



© Jenny Thompson/fotolia.com



INVITATION PROGRAMME Call for Abstracts / Scientific Programme

WFSBP Congress 2017

13th World Congress of Biological Psychiatry

18 – 22 June 2017

Copenhagen, Denmark

Bella Center Copenhagen

www.wfsbp-congress.org

Organised by: World Federation of Societies of Biological Psychiatry

Hosted by the Danish Society of Biological Psychiatry



Table of Contents

Page

3	Invitation to the 13th World Congress of Biological Psychiatry
4	About WFSBP
5	About the WFSBP Congress 2017
	Congress Administration
	WFSBP Executive Committee
	International Scientific Programme Committee
	Honorary Committee (HC)
	National Presidents
	Chairs of the Local Organising Committee (LOC)
	Congress Ambassadors
	Congress Programme
7	Colour Legend
8	Preliminary Scientific Programme Schedule
13	Preliminary Scientific Programme
39	Topics
40	Call for Abstracts for Free Communications and Posters
42	Format Descriptions of the Scientific Sessions
43	WFSBP Awards
44	Congress Information
45	General Information

WFSBP GLOBAL HEADQUARTERS

Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49-40-670 882 90
Fax: +49-40-670 328 82 91
Email: info@wfsbp.org
www.wfsbp-congress.org

CONGRESS VENUE

Bella Center Copenhagen
Center Boulevard 5
2300 Copenhagen S, Denmark
www.bellacentercopenhagen.dk

CONGRESS AND EXHIBITION OFFICE

CPOHANSER[®]
SERVICE

Phone: +49-30-300 669-0
Email: wfsbp2017@cpo-hanser.de

Invitation to the 13th World Congress of Biological Psychiatry



Masatoshi Takeda



Constantin R. Soldatos



Gregers Wegener

Dear Colleagues,

It is both an honor and a privilege to welcome all of you to the 13th World Congress of Biological Psychiatry in Copenhagen, 18–22 June 2017, which will be an excellent setting to discuss the current progress in molecular biology, the development of novel drugs based upon new concepts, and the advances in modern neuroscience that will change our approach to psychiatric disorders and our attitudes towards mental health care. It is the time for biological psychiatry to be developed into the new stage where biopsychosocial aspects are integrated for the betterment of patients and families with mental and psychiatric disorders. The field of biological psychiatry is expanding by the development of bioinformatics (genomics, transcriptomics, proteomics) identifying importance of glycome, lipidome, metabolome, and desease, and brain activity mapping methodology.

Looking back a few examples of previous world congress of biological psychiatry in Paris (2009), Prague (2011), Kyoto (2013), and Athens (2015), it is remarkable to have witnessed significant contribution of biological psychiatry research into the diagnosis, treatment, care, and even prevention of psychiatric and mental disorders.

The field of biological psychiatry is rapidly developing, reaching the new stage of clinical application. Genetic engineering, iPS cells, brain mapping, and other new technologies have been integrated into the translational research in the field. Modified electroconvulsive therapy (mECT), repetitive transcranial stimulation (rTMS), near-infrared spectroscopy (NIRS), and decoded neurofeedback (DecNef) are examples of recent application in biological psychiatry. Considering the impact of most CNS disorders, biological psychiatry is expected to fill in the unmet need for CNS drugs including new generation antipsychotics, anti-depressants, anti-epileptics, anxiolytics, and sleep inducers, and others. Biological psychiatry is the field where academia and industry should proceed together aiming for the developing of new methods of diagnosis and treatment of CNS disorders.

We are confident that the 13th World Congress of Biological Psychiatry in Copenhagen will be the superb setting for presentation and discussion of recent findings in biological psychiatry. To this end, 5 Lectures, 3 Debates, 12 Task Force Symposia/Workshops and 83 independent Symposia/Workshops are already forming the core scientific programme; all of them on very interesting topics to be presented by prominent researchers-scientists in their respective fields.

We trust that the breadth of topics our congress is tackling, will encourage many more colleagues around the world to submit their recent findings, through our Free Communication and Poster presentation sessions. For more information regarding relevant deadlines, please visit our congress website.

We are looking forward to meeting you in Copenhagen and interacting with you both socially and professionally.

With our best wishes

Prof. Masatoshi Takeda
Congress President

Prof. Constantin R. Soldatos
*Chair of the International
Scientific Programme
Committee*


Prof. Gregers Wegener
*Chair of the Local
Organising Committee*

About WFSBP

Founded in 1974 in Buenos Aires, Argentina, the World Federation of Societies of Biological Psychiatry is a non-profit world wide organization composed of 63 National Societies of Biological Psychiatry and Individual Members representing professionals from over 70 countries.

With this multitude of countries represented in its worldwide community, the World Federation has built an international network of over 4,500 opinion leaders, the majority of which are key opinion-leaders in the practice of Biological Psychiatry.

WFSBP members by continent



As of December 2015




The principle objectives of WFSBP are:

- ▶ To foster and encourage scientific research and advancement in the field of Biological Psychiatry
- ▶ To improve the quality of training spanning all the biological psychiatry sciences
- ▶ To promote education and achieve the highest level of knowledge and understanding within the field
- ▶ To provide information and guidance to all institutions, societies or individuals with an interest in biological psychiatry
- ▶ To establish, build, and maintain solid collaboration with international and national organisations related to biological psychiatry

Educational activities, regional, international and world congresses, the interactive website www.wfsbp.org, and The World Journal of Biological Psychiatry build the World Federation's portfolio and insure its worldwide influence. The development of worldwide treatment guidelines is one of WFSBP's main areas of international leadership.

Year after year, more and more professionals choose to join the World Federation's Biological Psychiatry arena and enjoy its exclusive educational and networking opportunities. In the coming years WFSBP is looking forward to welcoming over 15 new eminent member societies from different parts of the world.

WFSBP members by field of activity:



About the WFSBP Congress 2017

CONGRESS ADMINISTRATION

The 13th World Congress of Biological Psychiatry will be organised by the World Federation of Societies of Biological Psychiatry (WFSBP)

WFSBP EXECUTIVE COMMITTEE

President (2015 – 2019)

Masatoshi Takeda, Japan

Vice President (2013 – 2017)

Tudor Udristoiu, Romania

Past President (2015 – 2017)

Constantin R. Soldatos, Greece

Secretary (2013 – 2017)

Lakshmi N. Yatham, Canada

Treasurer (2013 – 2017)

Martin Hatzinger, Switzerland

Vice Secretary (2013 – 2017)

Ladislav Hosak,
Czech Republic

Vice Treasurer (2013 – 2017)

Victoria Valdez, Ecuador

INTERNATIONAL SCIENTIFIC PROGRAMME COMMITTEE (ISPC)

Chair

Constantin R. Soldatos, Greece

Vice Chairs

Peter Falkai, Germany
Lakshmi Yatham, Canada

Deputy Chairs

Dimitris Dikeos, Greece
Yoshio Hirayasu, Japan
Tudor Udristoiu, Romania

Secretary

Georgios Kiosterakis, Greece

Members of ISPC

G. Alexopoulos, USA*

C. A. Altamura, Italy*

C. Arango, Spain

E. Baca Garcia, Spain

M. Bauer, Germany*

E. Belfort, Venezuela

A. Benyamina, France

M. Berk, Australia*

J. Bobes, Spain

A. Bozkurt, Cyprus

N. Boutros, USA

C. L. Bowden, USA

P. Boyer, France

J. Bradford, Canada

P. Brambilla, Italy

M. Bras, Croatia

M. S. Buchsbaum, USA

A. Burns, UK

R. Castilla-Puentes, USA*

D. Castle, Australia*

E. Ceskova, Czech Republic*

M. Cetkovich-Bakmas, Argentina

Y. Hwa Chou, Taiwan*

H. Correa, Brazil*

P. Cosyns, Belgium

P. Courtet, France*

B. Dean, Australia*

J. de Buitelaar, The Netherlands

M. Dierick, Belgium

B. Dubois, France

K. Fountoulakis, Greece*

S. Frangou, UK

W. Gaebel, Germany

F. D. Garcia, Brazil*

W. F. Gattaz, Brazil

P. Gejman, USA

A. Germanavicious, Lithuania

M. George, USA*

A. H. Glassman, USA

B. Glenthøj, Denmark

G. M. Goodwin, UK

D. Gorelick, USA

P. Gorwood, France*

A. Grace, USA*

H. Grunze, UK*

G. Hajak, Germany

A. Halaris, USA*

A. Hasan, Germany

S. Heckers, USA

C. Hiemke, Germany

E. Hollander, USA

E. Holsboer-Trachsler, Switzerland*

W. G. Honer, Canada

J. Horacek, Czech Republic

A. Jablensky, Australia

R. Kahn, The Netherlands

J. Kane, USA

S. Kanba, Japan*

T. Kato, Japan

C. Katona, UK

W. Kaye, USA

J. Kennedy, Canada*

L. Konopka, USA

H. R. Kranzler, USA*

C. Krieg, Germany

T. Kudo, Japan

J. Soo Kwon, Korea

S. Lamy, France

R. Lanzenberger, Austria*

V. Larach, Chile

M. Leboyer, France

M.S. Lee, Korea*

M. Lejoyeux, France

B. Leonard, Ireland*

Y. Levkovitz, Israel

A. Lopez Mato, Argentina*

C. Lyketsos, USA

* Special correspondents of ISC Core Group



About the WFSBP Congress 2017

R. McCarley, USA
P. Mc Gorry, Australia
P. Mc Guire, UK
M. Maes, Belgium*
A. Malafosse, Switzerland
J.-L. Martinot, France
V. Matei, Romania*
H. Mayberg, USA
H. Y. Meltzer, USA
A. Meyer-Lindenberg, Germany
A. Kant Mital, India
E. Mohan Das, India
N. Müller, Germany
T. Murai, Japan*
Z. Nahas, Lebanon
D. Nutt, UK
J. Ospina-Duque, Colombia*
N. Ozaki, Japan
C. Pantelis, Australia*
G. Papadimitriou, Greece
T. Paparrigopoulos, Greece*
G. Parker, Australia
L. Pezewas, Austria
O. Pogarell, Germany
S. G. Potkin, USA
R. Post, USA*
M. Rapaport, USA
M.S. Reddy, India*
E. Richelson, USA
P. Riederer, Germany
D. Rujescu, Germany
R. Rupprecht, Germany
J. Rybakowski, Poland
H. Sackeim, USA
T. Saito, Japan
P. Salgado Pineda, Spain
M. Sarchiapone, Italy
T. Schlaepfer, Germany*
A. Schmitt, Germany
L. Schneider, USA
C. Schulz, USA
T. G. Schulze, Germany*
S. Seedat, South Africa*
E. Seifritz, Switzerland
A. Serretti, Italy*
E. Serfaty, Argentina
W. W. Shen, Taiwan

L. Siever, USA
D. St. Clair, UK
N. Stefanis, Greece*
J. Steiner, Germany
T. Suhara, Japan
M. Taleb, France/Algeria
T. Taneli, USA
J. Tellez-Vargas, Colombia
J. Treasure, UK
N. A. Uranova, Russia
P. Udomratn, Thailand*
I. Udristoiu, Romania*
W. van den Brink, The Netherlands*
J. van Os, The Netherlands
D. Velakoulis, Australia*
N. Venizelos, Sweden*
E. Vieta, Spain*
J. Waddington, Ireland
A. Weinstein Israel
P. Whybrow, USA
X. Yu, China
M. Zanarini, USA
Y. Zervas, Greece*
J. Zohar, Israel

HONORARY COMMITTEE (HC)

Jules Angst, Switzerland
Jose Luis Ayuso, Spain
Jorge Ciprian-Ollivier, Argentina
Jorge Alberto Costa e Silva, Brazil
Tetsuo Fukuda, Japan
Gerardo Heinze, Mexico
Carlos Roberto Hojaij, Brazil
Florian Holsboer, Germany
Siegfried Kasper, Austria
Jeffrey Lieberman, USA
Julien Mendlewicz, Belgium
Hans-Jürgen Möller, Germany
Robin Murray, UK
Ahmed Okasha, Egypt
Mitsumoto Sato, Japan
Norman Sartorius, Switzerland
Göran Sedvall, Sweden
Costas Stefanis, Greece
Florence Thibaut, France
Michael Trimble, UK

NATIONAL PRESIDENTS

A. Corrales, Argentina
A. Boyajyan, Armenia
C. Geretsegger, Austria
S. Claes, Belgium
N. D. Noya-Tapia, Bolivia
A. Kucukalic, Bosnia-Herzegovina
A. Marcolin, Brazil
O. Atanasova Mikova-Demireva, Bulgaria
R. W. Lam, Canada
E. Olea, Chile
C. Gutierrez, Columbia
R. Castro, Costa Rica
M. Jakovljevic, Croatia
L. Hosak, Czech Republic
G. Wegener, Denmark
F. Solis de Mendez, Dominican Republic
M. Meneses-Guevara, Ecuador
A. Okasha, Egypt
M. Meija Pena, El Salvador
J. Harro, Estonia
P. Courtet, France
S. Herpertz, Germany
C. R. Soldatos, Greece
H. Soto Chavez, Guatemala
M. Aguilar Lopez, Honduras
S.-W. Tang, Hong Kong
C. Banki, Hungary
R. Nagpal, India
A. J. Tanra, Indonesia
D. Gothelf, Israel
M. Maj, Italy
T. Nishikawa, Japan
M. Assimov, Kazakhstan
C. Uk Lee, Korea
B. Kupca, Latvia
C. Baddoura, Libanon
J. Neveranskas, Lithuania
B. Stefanovski, Macedonia
S. Krishnaswamy, Malaysia
D. Moussaoui, Morocco
G. Villanueva Colin, Mexico
H. Lovdahl, Norway
M. Amin, Pakistan
G. Da Costa, Panama

* Special correspondents of ISC Core Group

About the WFSBP Congress 2017 / Colour Legend

L. Villalba, Paraguay
 E. Galli, Peru
 A. Wichniak, Poland
 J. Relvas, Portugal
 T. Udristoiu, Romania
 S. Mosolov, Russia
 N. Maric Bojovic, Serbia
 L. Vavrusova, Slovakia
 S. Seedat, South Africa
 M. Bernardo, Spain
 M. Ramklint, Sweden
 M. Hatzinger, Switzerland
 Ch.-Y. Liu, Taiwan
 P. Udomratn, Thailand
 B. Taneli, Turkey
 A. V. Kalueff, Ukraine
 G. Bouza, Uruguay
 J. Ibáñez-Domínguez, Venezuela

CHAIRS OF THE LOCAL ORGANISING COMMITTEE (LOC)

Chair

Gregers Wegener, Denmark

Deputy Chairs

Ida Hageman, Denmark
 Søren Dinesen Østergaard, Denmark

Members of LOC

Kjeld Andersen, Denmark
 Ole A. Andreassen, Norway
 Lone Baandrup, Denmark
 Per Bech, Denmark
 Nils Bilenberg, Denmark
 Bjørn Ebdrup, Denmark
 Jesper Ekelund, Finland
 Anders Fink-Jensen, Denmark
 Birte Glenthøj, Denmark
 Simon Glerup, Denmark
 Jaanus Harro, Estonia
 Torsten Bjørn Jacobsen, Denmark
 Martin Balslev Jørgensen, Denmark
 Olli Kampman, Finland
 Lars Kessing, Denmark
 Gitte Moos Knudsen, Denmark
 Rasmus Licht, Denmark
 Pall Mathiasson, Iceland
 Tanja Michel, Denmark
 Thomas Middelboe, Denmark
 Ole Mors, Denmark
 Merete Nordentoft, Denmark
 Kerstin Plessen, Denmark
 Andreas Reif, Germany
 Dan Rujescu, Germany
 Bo Söderpalm, Sweden
 Per Hove Thomsen, Denmark
 Jari Tiihonen, Sweden
 Anders Tingström, Sweden
 Poul Videbech, Denmark
 Thomas Werge, Denmark

CONGRESS AMBASSADORS

Carlo Altamura, Italy
 Ajit Avasthi, India
 Charles Baddoura, Libanon
 Robert Belmaker, Israel
 Enrique Galli, Peru
 Peter Gaszner, Hungary
 Bai Han, China
 Gerhard Heinze, Mexico
 Nick Kates, Canada
 Donatella Marazziti, Italy
 Giorgio Racagni, Italy
 M.S. Reddy, India
 Pedro Ruiz, USA
 Janusz Rybakowski, Poland
 Dan Stein, South Africa
 Andi J. Tanra, Indonesia
 Si Tian-Mei, China
 Eduard Vieta, Spain
 Shigeto Yamawaki, Japan
 Yukio Yoneda, Japan
 Allan Young, UK

COLOUR CODES OF SESSIONS (PRELIMINARY SCIENTIFIC PROGRAMME, PAGES 8 – 38)

OP	Opening Lecture
PL	Plenary Lectures
D	Debates

TFS	Task Force Symposia
TFW	Task Force Workshops
S	Symposia

WS	Workshops
FC	Free Communications
SA	Satellite Symposia

Preliminary Scientific Programme Schedule / Sunday, 18 June 2017

8:30	S-01 Towards novel rapid-acting antidepressants	S-02 Psychiatric services in emergency departments: Challenges and solutions	S-03 Dissecting the role of the neurotrophin Brain Derived Neurotrophic Factor in cocaine addiction: Clues from clinical and preclinical studies	WS-01 Initiatives from the Spanish Society of Biological Psychiatry: From evidence to experience	Free Communications
9:00					
9:30					
10:00					
10:30	S-04 Pathways of neuroprogression in Bipolar Disorder (BP)	S-05 Extracellular vesicles in neuropsychiatric diseases: Basic mechanisms and biomarkers	S-06 Drug addiction and GPCR heteroreceptor complexes: What goes wrong in receptor plasticity as addiction develops?	WS-02 New investigations on the relationship between working memory and ADHD	Free Communications
11:00					
11:30					
12:00					
12:30	S-07 Social cognition and neuronal correlates in patients with schizophrenia	S-08 Inflammation markers of peripheral blood in depression spectrum	Satellite Symposia		Free Communications
13:00					
13:30					
14:00					
14:30	S-09 Mechanisms contributing to neuroprogression in psychiatric disorders and promising interventions	S-10 Effects and side effects of electroconvulsive therapy	S-11 Abnormal neurogenesis in schizophrenia	S-12 New approaches into diagnosis and treatment of psychotic Bipolar Disorder (BP)	Free Communications
15:00					
15:30					
16:00					
16:30	S-13 Biomarkers for early diagnosis of Alzheimer's Disease (AD) and other neurodegenerating diseases: Advantages and limitations	Satellite Symposia			Free Communications
17:00					
17:30					
18:00	Opening Ceremony 18:00 – 19:00				
18:30	(incl. OP-01 The microbiome-gut-brain axis: A key regulator of brain & behaviour across the lifespan)				
	Registration Counter 07:30 – 19:00				

Monday, 19 June 2017 / Preliminary Scientific Programme Schedule

8:30	S-14 Problematic sexual behaviors: Diagnostic, categorical, epidemiological, imaging, psychopathological and treatment considerations	S-15 Posttraumatic Stress Disorder (PTSD) and gender	S-16 The elephant in the room: The role of glial cells in psychiatric disorders	S-17 Psychosis is disrespectful to diagnostic boundaries: Nosological and pathobiological implications of psychoses beyond ...	S-18 Epigenetic modification, effect of early life stress, and signaling mechanisms in suicide	S-19 Psychedelics: Mechanisms and applications in psychiatry	S-20 Affective and psychotic psychopathology from pregnancy to early adulthood: The dynamic developmental interplay ...	Free Communications
9:00								
9:30								
10:00								
10:30	Plenary Lecture PL-01 Drug discovery in neuroscience: Promises, barriers and opportunities							
11:00								
11:30	D-01 Antidepressants are effective for treating acute bipolar depression	TFS-01 Therapeutic drug monitoring, pharmacogenetics and brain imaging methods as tools for optimizing pharmacotherapy in psychiatry	S-21 Measurement-based psychiatry: Toward rating scale-based assessments in the real world	S-22 Dissecting the shared and non-shared biological features in schizophrenia and autism spectrum disorder	S-23 Combining cognitive remediation with brain imaging techniques: Evidence for neural changes or neuroplasticity?	WS-03 Current status of electroconvulsive therapy in the treatment of major psychiatric disorders	S-24 Serotonin and anxiety disorders: Recent evidences from neuroimaging studies	Free Communications
12:00								
12:30								
13:00								
13:30								
14:00	Satellite Symposia							
14:30								
15:00	S-25 tDCS: From research to clinical practice	TFS-02 Post-mortem findings across psychiatric disorders and their association with cognitive symptoms	TFW-01 Workshop of the WFSBP Task Force on Genetics: Focus on pharmacogenomics	S-26 Into novel drugs for depression	S-27 Beyond unitary models of psychosis: Confronting complex etiology and dimensionality	WS-04 Rethinking depression in the Century XXI: Where are we now in biological psychiatry?	S-28 Wake and sleep electroencephalogram provide biomarkers of depression	Free Communications
15:30								
16:00								
16:30								
17:00	S-29 Autism spectrum disorders in adults – from the clinical phenotype to the underlying neurobiology – novell technics such ...	TFS-03 Update biomarkers in psychiatry	Satellite Symposia				Free Communications	
17:30								
18:00								
18:30								
Registration Counter 08:00 – 18:30				Poster Exhibition 09:00 – 17:00				Technical Exhibition 09:00 – 17:00



Preliminary Scientific Programme Schedule / Tuesday, 20 June 2017

8:30	S-30 Recent insights in schizophrenia pathophysiology and treatments	S-31 Duration of untreated psychosis: From neuroimaging to clinical trials	S-32 New perspectives on transcranial magnetic stimulation in psychiatric disorders	S-33 Epigenetic biomarkers for the diagnosis of mood disorders	S-34 Sex hormones and their wide-ranging effects on psychopathology	WS-05 Gesture as window to psychosis pathobiology: From aberrant body experience to social interaction	S-35 New insights into the neurobiology and treatment aspects of obsessive compulsive disorder comorbid with schizophrenia and bipolar ...	Free Communications
9:00								
9:30								
10:00	<p style="text-align: center;">Plenary Lecture</p> <p style="text-align: center;">PL-02 Novel treatments in mood disorders: Molecular mechanisms and clinical applications</p>							
10:30								
11:00	D-02 The Research Domain Criteria (RDoC) can create a new kind of taxonomy holding greater promise compared to the traditional ...	TFS-04 Sleep in depression and cognition – from research to clinical practice	S-36 The role of the nucleus accumbens in psychiatry	S-37 Neurobiologic imaging studies of mood disorders, neurogenetics and antidepressant action with positron emission tomography	S-38 Treatment resistant schizophrenia: Definitions, psychobiology and clinical treatment	WS-06 Neurobiology of suicidal behaviour	Free Communications	
11:30								
12:00								
12:30								
13:00	<p style="text-align: center;">Satellite Symposia</p>							
13:30								
14:00								
14:30								
15:00	WS-07 Merging evidence and clinical practice in management of depression: The CANMAT experience	TFS-05 Biomarkers for schizophrenia: From molecules to brain function. A consensus of the WFSBP Task Force on biological markers	TFW-02 WFSBP Consensus on the management of agitation in psychiatry	S-39 Current research on the use of cannabinoids	S-40 Alzheimer's Disease (AD) pathophysiology, prevention and treatment strategies: Where we stand and where we go?	WS-08 Functional neuroanatomy of hallucinations	S-41 Electroconvulsive therapy for depression – optimising treatment and maintaining recovery	Free Communications
15:30								
16:00								
16:30								
17:00	S-42 Neuroepigenetic approaches to assess disease risk, mechanism and treatment	TFS-06 Electroconvulsive therapy: Beyond depression	<p style="text-align: center;">Satellite Symposia</p>					Free Communications
17:30								
18:00								
18:30								
	Registration Counter 08:00 – 18:30			Poster Exhibition 09:00 – 17:00			Technical Exhibition 09:00 – 17:00	

Wednesday, 21 June 2017 / Preliminary Scientific Programme Schedule

8:30	S-43 Novel approaches in mechanisms of action of antidepressant treatment	S-44 Cannabinoid Receptor (CBR) gene variations in neuropsychiatric disorders	S-45 Behavioral Addictions: Diagnosis, co-morbidity and neurobiology	S-46 Neurobiology and psychopharmacology of aggressive behaviour: Where are we?	S-47 Catecholamines, anhedonia and depression	Free Communications	
9:00							
9:30							
10:00	Plenary Lecture						
10:30	PL-03 Epigenetic consequences of early adversity: Implications for psychiatric disorders						
11:00						Free Communications	
11:30	D-03 Deep brain stimulation is a worthwhile treatment method in psychiatry	TFS-07 Enhancing the role of primary care in looking after people with mental health problems: A new position paper from the Collaborative ...	S-48 Pharmacogenetics of drug defense and neuroprotection: From the Neandertal to the modern humans	S-49 Evidence-based guidelines for treatment of major depressive disorder: Contrasting views across the world	S-50 Real time assessment of psychopathology and behavior in Bipolar Disorder (BP) using e-mental health technologies		WS-09 Schizophrenia research in Chile
12:00							
12:30							
13:00	Satellite Symposia						
13:30	Satellite Symposia						
14:00	Satellite Symposia						
14:30	Satellite Symposia						
15:00	S-51 Advances in biomarker development for neurostimulation	TFS-08 Men's mental health: Contemporary aspects	TFW-03 WFSBP Treatment Guideline Session: Do bipolar mixed states merit a treatment guideline on its own?	S-52 The G protein coupled receptors as a target for psychotropic drugs	S-53 Suicidal behavior: Neurobiological and genetic determinants	WS-10 Evidence for brain stimulation methods in schizophrenia	Free Communications
15:30							
16:00							
16:30	Satellite Symposia						
17:00	S-54 Lithium as a neuroprotective agent: When and how?	TFS-09 Providing acute inpatient care for children, adolescents and young adults from a men's mental health perspective: Focus on ...	S-55 Rediscovering Lithium	Satellite Symposia		Free Communications	
17:30							
18:00							
18:30	Satellite Symposia						
	Registration Counter 08:00 – 18:30			Poster Exhibition 09:00 – 17:00		Technical Exhibition 09:00 – 17:00	



Preliminary Scientific Programme Schedule / Thursday, 22 June 2017

8:30	S-56 Clinical effects and neural mechanisms of electro-convulsive therapy in major depression and schizophrenia	S-57 Causes and consequences of inflammation in Bipolar Disorder (BP)	S-58 Novel therapeutics for neurodegenerative disorders	S-59 The relevance of Neuregulin1-ErbB4 signaling for neuropsychiatric pathomechanisms: Converging insights from mouse ...	S-60 Multi-omics and psychiatry: The missing molecular link	S-61 Suicide: Aspects that burn	Free Communications						
9:00													
9:30													
10:00	Plenary Lecture PL-04 Lithium in mood disorders including a homage to Danish contribution												
10:30													
11:00	S-62 Innovative approaches in suicide research	S-63 Atypical neurotransmitters in psychiatry: Relevance for future therapeutics	S-64 Operationalizing the dysconnection syndrome: Translational approaches reveal brain network dysfunction in schizophrenia	S-65 Cell-type specific epigenetic, proteomic and gene expression signatures in schizophrenia: New findings from post-mortem ...	S-66 NMDA receptor antagonists in psychiatry	S-67 Spectrum of Mood Disorders (MD): Where is the place for mixed states?	Free Communications						
11:30													
12:00													
12:30	Satellite Symposia												
13:00													
13:30													
14:00													
14:30	Free Communications												
15:00								S-68 Dynamical brain: How brain complexity changes with aging and mental illness?	S-69 Increased intestinal permeability and bacterial translocation in neuro-psychiatric disorders	S-70 Current use of EEG-based techniques in psychiatry	S-71 Sex-specific neuroendocrinological findings in conduct disorder	S-72 Socio-demographic and clinical differences between Bipolar I and II Disorder (BP) and implications for treatment	S73 Neuropathologic implication of abnormal cortico-basal ganglia connectivity in schizophrenia hallucination and its models
15:30													
16:00													
16:30	Closing Ceremony												
17:00													
17:30													
18:00													
18:30													
	Registration Counter 08:00 – 17:30			Poster Exhibition 09:00 – 17:00									

Opening Lecture, Plenary Lectures, Debates / Preliminary Scientific Programme

Opening Lecture

► Sunday, 18 June 2017

OP-01

18:00–19:00

The microbiome-gut-brain axis: A key regulator of brain & behaviour across the lifespan

Chair: Masatoshi Takeda, Japan

Speaker: John F. Cryan, Ireland

Plenary Lectures

► Monday, 19 June 2017

PL-01

10:15–11:00

Drug discovery in neuroscience: Promises, barriers and opportunities

Chair: Lakshmi Yatham, Canada

Speaker: Husseini Manji, USA

► Tuesday, 20 June 2017

PL-02

10:15–11:00

Novel treatments in mood disorders: Molecular mechanisms and clinical applications

Chair: Gregers Wegener, Denmark

Speaker: Carlos Zarate, USA

► Wednesday, 21 June 2017

PL-03

10:15–11:00

Epigenetic consequences of early adversity: Implications for psychiatric disorders

Chair: Constantin R. Soldatos, Greece

Speaker: Elisabeth Binder, Germany

► Thursday, 22 June 2017

PL-04

10:15–11:00

Lithium in mood disorders including a homage to Danish contribution

Chair: Tudor Udristoiu, Romania

Speaker: Janusz Rybakowski, Poland

Debates

► Monday, 19 June 2017

D-01

11:15–12:45

Antidepressants are effective for treating acute bipolar depression

Chair: Lakshmi Yatham, Canada

Proponent: Glenda MacQueen, Canada

Opponent: Robert Post, USA

► Tuesday, 20 June 2017

D-02

11:15–12:45

The Research Domain Criteria (RDoC) can create a new kind of taxonomy holding greater promise compared to the traditional Nosological Classification Systems in psychiatry

Chair: Sabine Herpertz, Germany

Proponent: Andreas Heinz, German

Opponent: Henning Saß, Germany

► Wednesday, 21 June 2017

D-03

11:15–12:45

Deep brain stimulation is a worthwhile treatment method in psychiatry

Chair: Gregers Wegener, Denmark

Proponent: Thomas Schlöpfer, Germany

Opponent: Marwan Hariz, United Kingdom

Preliminary Scientific Programme / WFSBP Task Force Symposia

WFSBP Task Force Symposia

► **Monday, 19 June 2017**

T51: PSYCHOPHARMACOLOGY

TFS-01

11:15–12:45

Therapeutic drug monitoring, pharmacogenetics and brain imaging methods as tools for optimizing pharmacotherapy in psychiatry

Chair: *Chin B. Eap, Switzerland*

Co-Chair: *Christoph Hiemke, Germany*

TFS-01-001

Pharmacogenetics in psychiatry

Chin B. Eap, Switzerland

TFS-01-002

Therapeutic drug monitoring in psychiatry

Christoph Hiemke, Germany

TFS-01-003

Brain imaging in psychiatry

Gerhard Gründer, Germany

TFS-01-004

Strategies for the implementation of genetic biomarkers in clinical practice

Daniel Müller, Canada

T24: NEUROPATHOLOGY

TFS-02

15:00–16:30

Post-mortem findings across psychiatric disorders and their association with cognitive symptoms

Chair: *Andrea Schmitt, Germany*

Co-Chair: *Johann Steiner, Germany*

TFS-02-001

Alterations in hippocampal oligodendrocyte and neuron number in patients with schizophrenia, Bipolar Disorder (BP) and major depression

Peter Falkai, Germany

TFS-02-002

GABAergic system impairment in the hippocampus and superior temporal gyrus of patients with paranoid schizophrenia

Johann Steiner, Germany

TFS-02-003

Presynaptic contributions to cognitive reserve

William Honer, Canada

TFS-02-004

Different changes in cortical muscarinic receptors in psychiatric and neurological disorders

Brian Dean, Australia

T22: MOLECULAR NEUROBIOLOGY

TFS-03

17:00–18:30

Update biomarkers in psychiatry

Chair: *Peter Riederer, Germany*

Co-Chair: *Peter Falkai, Germany*

TFS-03-001

Biomarkers for schizophrenia

Florence Thibaut, France

TFS-03-002

Biological marker in alcoholism

Toshikazu Saito, Japan

TFS-03-003

Specificity of biomarkers for OCD/ADHD

Edna Grünblatt, Switzerland

TFS-03-004

Specificity of biomarkers for anxiety

Borwin Bandelow, Germany

► **Tuesday, 20 June 2017**

T11: DEPRESSION: BASIC/CLINICAL

TFS-04

11:15–12:45

Sleep in depression and cognition – from research to clinical practice

Chair: *Edith Holsboer-Trachsler, Switzerland*

Co-Chair: *Birendra N. Mallick, India*

TFS-04-001

Sleep as biomarker: Predictor of emotional regulation and depression

Martin Hatzinger, Switzerland

TFS-04-002

Sleep in dementia: A biomarker of cognition?

Dimitris Dikeos, Greece

TFS-04-003

Sleep and synaptic dysfunction in depression

Anne Eckert, Switzerland

TFS-04-004

REM sleep and prevention of neurodegeneration: Role of noradrenaline

Birendra N. Mallick, India

WFSBP Task Force Symposia / Preliminary Scientific Programme

T43: SCHIZOPHRENIA: BASIC / CLINICAL

TFS-05

15:00–16:30

Biomarkers for schizophrenia: From molecules to brain function. A consensus of the WFSBP Task Force on biological markers

Chair: Andrea Schmitt, Germany

Co-Chair: Daniel Martins de Souza, Brazil

TFS-05-001

Genetic biomarkers

Dan Rujescu, Germany

TFS-05-002

Neuroimaging biomarkers

Nikolaos Koutsouleris, Germany

TFS-05-003

Molecular biomarkers

Daniel Martins de Souza, Brazil

TFS-05-004

Cognition biomarkers

Peter Falkai, Germany

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

TFS-06

17:00–18:30

Electroconvulsive therapy: Beyond depression

Chair: Georgios Petrides, USA

Co-Chair: William McDonald, USA

TFS-06-001

ECT for the treatment of catatonia

Tom Bolwig, Denmark

TFS-06-002

ECT in autism spectrum disorders: Catatonia and beyond

Lee Wachtel, USA

TFS-06-003

ECT for agitation in elderly patients with dementia

Adriana Hermida, USA

TFS-06-004

ECT-related mortality rates

Søren Dinesen Østergaard, Denmark

► Wednesday, 21 June 2017

T20: LIAISON PSYCHIATRY

TFS-07

11:15–12:45

Enhancing the role of primary care in looking after people with mental health problems: A new position paper from the Collaborative Care Task Force of the WFSBP

Chair: Nick Kates, Canada

TFS-07-001

Improving primary mental health care – Definitions, models, principles and challenges

Nick Kates, Canada

TFS-07-002

Integrating mental health services within primary care settings

Henrikje Klasen, The Netherlands

TFS-07-003

The role of the family physician in delivering mental health care

Torleif Ruud, Norway

TFS-07-004

Capacity building, training and adapting the approach for different countries

Nick Kates, Canada

T51: MEN'S MENTAL HEALTH

TFS-08

15:00–16:30

Men's mental health: Contemporary aspects

Chair: Leo Sher, USA

Co-Chair: Timothy Rice, USA

TFS-08-001

Future research and clinical directions in the field of men's mental health

Leo Sher, USA

TFS-08-002

Towards a neuropsychiatric model of disruptive behavior disorders in boys and young men: Developmental deficits in the emotion regulation system, their origin, and their therapeutic address

Timothy Rice, USA

TFS-08-003

Sex differences in addictive disorder and its clinical connotation

Shih-Ku Lin, Taiwan



Preliminary Scientific Programme / WFSBP Task Force Symposia and Workshops

TFS-08-004

Sex differences in early predictors of adult personality and intelligence

Trine Flensburg-Madsen, Denmark

T50: VIOLENCE: BASIC/CLINICAL

TFS-09

17:00–18:30

Providing acute inpatient care for children, adolescents and young adults from a men's mental health perspective: Focus on violence reduction

Chair: Pilar Trelles, USA

Co-Chair: Lesha Shah, USA

TFS-09-001

Brain development: A focus on normal male development and psychopathology

Pilar Trelles, USA

TFS-09-002

Asking for the IM: What to do when the disruptive male child appears to seek punishment

Timothy Rice, USA

TFS-09-003

Agression in adolescence

Lesha Shah, USA

TFS-09-004

Violent and suicidal behavior among young male veterans on an inpatient psychiatric unit

Leo Sher, USA

TFW-01-003

Whole exom sequencing reveals risk factors in treatment resistant depression

Alessandro Serretti, Italy

TFW-01-004

Pharmacogenetic discoveries and applications in psychiatric populations

Jim Kennedy, Canada

► Tuesday, 20 June 2017

T13: EMERGENCY PSYCHIATRY

TFW-02

15:00–16:30

WFSBP consensus on the management of agitation in psychiatry

Chair: Siegfried Kasper, Austria

Co-Chair: Eduard Vieta, Spain

TFW-02-001

Agitation: Causes and differential diagnosis

Marina Garriga, Spain

TFW-02-002

Agitation in schizophrenia

Dieter Naber, Germany

TFW-02-003

Agitation in Bipolar Disorder (BP)

Lakshmi Yatham, Canada

TFW-02-004

WFSBP Consensus on agitation in psychiatry

Eduard Vieta, Spain

► Wednesday, 21 June 2017

T6: BIPOLAR DISORDERS: BASIC/CLINICAL

TFW-03

15:00–16:30

WFSBP Treatment Guideline Session: Do bipolar mixed states merit a treatment guideline on its own?

Chair: Siegfried Kasper, Austria

Co-Chair: Heinz Grunze, United Kingdom

TFW-03-001

Clinical manifestations of bipolar mixed states-epidemiological and clinical research

Jean-Michel Azorin, France

TFW-03-002

The changing concept of mixed states over time: DSM5 broadening and downgrading at the same time

Eduard Vieta, Spain

WFSBP Task Force Workshops

► Monday, 19 June 2017

T32: PHARMACOGENETICS

TFW-01

15:00–16:30

Workshop of the WFSBP Task Force on genetics: Focus on pharmacogenomics

Chair: Dan Rujescu, Germany

Co-Chair: Jim Kennedy, Canada

TFW-01-001

Pharmacogenetics in schizophrenia

Rainald Mössner, Germany

TFW-01-002

Largest genome wide association study on agranulocytosis under Clozapine

Dan Rujescu, Germany

WFSBP Task Force Workshops, Symposia / Preliminary Scientific Programme

TFW-03-003

The WFSBP Treatment guideline for mixed states-evidence and recommendations

Heinz Grunze, United Kingdom

TFW-03-004

What the CINP guideline recommends in mixed states

Konstantinos Fountoulakis, Greece

Symposia

► **Sunday, 18 June 2017**

T2: ANTIDEPRESSANTS: BASIC / CLINICAL

S-01

08:30–10:00

Towards novel rapid-acting antidepressants

Chair: Tomi Rantamäki, Finland

Co-Chair: Gregers Wegener, Denmark

S-01-001

Rapid acting antidepressants in chronic pain

Ipek Yalcin, France

S-01-002

Morphological and structural alterations following rapid acting antidepressants

Gregers Wegener, Denmark

S-01-003

Antidepressant potential of cannabidiol: Preclinical evidence

Sâmia Joca, Brazil

S-01-004

Anesthetics as rapid-acting antidepressants

Tomi Rantamäki, Finland

T20: LIAISON PSYCHIATRY

S-02

08:30–10:00

Psychiatric services in emergency departments: Challenges and solutions

Chair: Ruby Castilla-Puentes, USA

Co-Chair: Tatiana Falcone, USA

S-02-001

Psychiatric consultations in rural general hospitals – Latinos vs. Anglos

Bernardo Ng, USA

S-02-002

A study of insomnia and comorbid psychiatric conditions in rehabilitation clinics

Franklin Escobar, Colombia

S-02-003

Depression and medical comorbidity in emergency departments in Mexico

Ricardo Secin, Mexico

S-02-004

Self-inflicted injury in children and adolescents: A study in a tertiary care hospital in Santiago de Chile

Arturo Grau, Chile

T1: ADDICTIVE DISORDERS

S-03

08:30–10:00

Dissecting the role of the neurotrophin Brain Derived Neurotrophic Factor in cocaine addiction: Clues from clinical and preclinical studies

Chair: Fabio Fumagalli, Italy

S-03-001

Acute exposure to cocaine during brain development evokes depressive-like behaviors via downregulation of Brain Derived Neurotrophic Factor signaling

Fabio Fumagalli, Italy

S-03-002

Cocaine and orbitofrontal cortical Brain Derived Neurotrophic Factor deficiency induce habit-based decision-making: Blockade by trkB stimulation

Shannon Gourley, USA

S-03-003

Systemic administration of the brain-penetrant TrkB antagonist cyclotraxin-b reduces short and long access cocaine intake

Michel Verheij, The Netherlands

S-03-004

Brain Derived Neurotrophic Factor and cocaine in clinical samples: A useful biomarker for treatment?

Lisia von Diemen, Brazil

T6: BIPOLAR DISORDERS: BASIC / CLINICAL

S-04

10:15–11:45

Pathways of neuroprogression in Bipolar Disorder (BP)

Chair: Benicio Frey, Canada

Co-Chair: Flavio Kapczinski, Brazil

S-04-001

Indicators of risk and resilience in the high-risk offspring of bipolar parents

Anne Duffy, Canada

Preliminary Scientific Programme / Symposia

S-04-002

Lithium compared to quetiapine in the maintenance phase after a first episode of mania

Michael Berk, Australia

S-04-003

Biological rhythms and illness progression in Bipolar Disorder (BP)

Benicio Frey, Canada

S-04-004

Illness trajectories and neuroprogression in Bipolar Disorder (BP)

Flavio Kapczinski, Brazil

T22: MOLECULAR NEUROBIOLOGY
S-05

10:15–11:45

Extracellular vesicles in neuropsychiatric diseases: Basic mechanisms and biomarkers

Chair: Takashi Kudo, Japan

Co-Chair: Dimitrios Kapogiannis, USA

S-05-001

Extracellular vesicles as a source of biomarkers for Alzheimer's Disease

Dimitrios Kapogiannis, USA

S-05-002

Tau inside neutrally-derived exosome

Dominic Walsh, USA

S-05-003

Mechanisms of exosome involvement in neurodegenerative diseases

Andrew Hill, Australia

S-05-004

Changes in exosomes proteins by the degree of stress

Takashi Kudo, Japan

T22: MOLECULAR NEUROBIOLOGY
S-06

10:15–11:45

Drug addiction and GPCR heteroreceptor complexes: What goes wrong in receptor plasticity as addiction develops?

Chair: Kjell Fuxe, Sweden

Co-Chair: Anita Hansson, Germany

S-06-001

Neurochemical mechanisms underlying goal-directed and habitual drug seeking and how these mechanisms produce compulsions: Focus on Gq-coupled glutamate receptors

Peter Kalivas, USA

S-06-002

Homo and heteroreceptor complexes participate in learning and memory and as an emerging target for treatment of cocaine addiction

Dasiel Borroto-Escuela, Sweden

S-06-003

Evidence for a role of A2A-D2 heteroreceptor complexes in cocaine addiction

Malgorzata Filip, Poland

S-06-004

Dopamine D4 –MOR interactions prevent nigrostriatal dopamine pathway activation by morphine: Relevance for drug addiction

Alicia Rivera, Spain

T43: SCHIZOPHRENIA: BASIC/CLINICAL
S-07

12:30–14:00

Social cognition and neuronal correlates in patients with schizophrenia

Chair: Gabriele Sachs, Austria

Co-Chair: Armida Mucci, Italy

S-07-001

Neurocognitive predictors of social cognition

Vijaya Lakshmi Valaparla, India

S-07-002

Emotional intelligence in patients suffering from schizophrenia and unaffected siblings

Alex Hofer, Austria

S-07-003

Social cognition and negative symptoms in schizophrenia: Constructs, assessment and relationships with functional outcome

Armida Mucci, Italy

Symposia / Preliminary Scientific Programme

S-07-004

Neurobiological correlates of the treatment of emotion processing in schizophrenia

Gabriele Sachs, Austria

T19: INFLAMMATION PSYCHIATRY

S-08

12:30–14:00

Inflammation markers of peripheral blood in depression spectrum

Chair: Piotr Galecki, Poland

Co-Chair: Angelos Halaris, USA

S-08-001

(Auto)immune biomarkers of depression and subtypes

Michael Maes, Thailand

S-08-002

Targeting inflammation to prevent depression

Michael Berk, Australia

S-08-003

Stratification of depressed patients by means of blood markers of inflammation, growth factors and kynurenine metabolites

Angelos Halaris, USA

S-08-004

Omega-3 fatty acids, inflammation and depression: From biological mechanisms to clinical application

Pin-Su Kuna, Taiwan

T39: PSYCHONEUROIMMUNOLOGY

S-09

14:30–16:00

Mechanisms contributing to neuroprogression in psychiatric disorders and promising interventions

Chair: Angelos Halaris, USA

S-09-001

Inflammatory and innate immune markers of neuroprogression in depressed and teenage suicide brain

Ghanshyam Pandey, USA

S-09-002

Major depression as a prelude to dementia: What is the evidence?

Brian Leonard, Ireland

S-09-003

Neuroimaging of microglia activation in major depression

Jeffrey Meyer, Canada

S-09-004

Promising neuroprotective and anti-inflammatory interventions to arrest neuroprogression

Angelos Halaris, USA

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-10

14:30–16:00

Effects and side effects of electroconvulsive therapy

Chair: Michael Grözinger, Germany

Co-Chair: Helge Frieling, Germany

S-10-001

Effects of ECT on the oxygen saturation in the frontal brain

Michael Grözinger, Germany

S-10-002

DNA methylation of P11/S100A10: A putative marker of response to ECT?

Helge Frieling, Germany

S-10-003

Electroconvulsive therapy enhances amyloid β 1-42 in the cerebrospinal fluid of patients with major depression

Alexander Sartorius, Germany

S-10-004

The EFFECT-Dep Trial (ISRCTN23577151): Immediate and long-term cognitive outcomes

Declan McLoughlin, Ireland

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-11

14:30–16:00

Abnormal neurogenesis in schizophrenia

Chair: Dragos Inta, Germany

Co-Chair: Guo-Li Ming, USA

S-11-001

Modeling predisposition to schizophrenia using hiPSCs

Kristen Brennand, USA

S-11-002

Neurogenesis and psychiatric neurodevelopmental disorders

Guo-Li Ming, USA

S-11-003

Precise activation of the Reelin pathway controls dendritic maturation, synapse formation and glial ensheathment of adult-generated granule cells

Eduardo Soriano, Spain

Preliminary Scientific Programme / Symposia

S-11-004
Adult neurogenesis in the striatum: Effect of psychiatric treatment

Dragos Inta, Germany

T6: BIPOLAR DISORDERS: BASIC / CLINICAL
S-12

14:30–16:00

New approaches into diagnosis and treatment of psychotic Bipolar Disorder (BP)

Chair: Carlo Altamura, Italy

Co-Chair: Allan Young, United Kingdom

S-12-001
Neuroimaging aspects of psychotic Bipolar Disorder (BP)

Paolo Brambilla, Italy

S-12-002
Candidate biomarkers for psychotic Bipolar Disorder (BP): The role of neuroinflammation and hormones

Massimiliano Buoli, Italy

S-12-003
Pharmacological treatment of psychotic Bipolar Disorder (BP)

Trisha Suppes, USA

T10: DEMENTIA: BASIC / CLINICAL
S-13 SYMPOSIUM

16:30–18:00

Biomarkers for early diagnosis of Alzheimer's Disease (AD) and other neurodegenerating diseases: Advantages and limitations

Chair: Piotr Lewczuk, Germany

Co-Chair: Henrik Zetterberg, Sweden

S-13-001
New developments in the biomarkers for Alzheimer's Disease (AD)

Kaj Blennow, Sweden

S-13-002
Amyloid beta 42/40 Ratio in diagnosis of AD: Do we need it?

Piotr Lewczuk, Germany

S-13-003
Sensitive technologies for blood biomarkers in neurodegeneration

Henrik Zetterberg, Sweden

S-13-004
Current diagnostic approaches in frontotemporal lobar degeneration

Markus Otto, Germany

► Monday, 19 June 2017
T1: ADDICTIVE DISORDERS
S-14

08:30–10:00

Problematic sexual behaviors: Diagnostic, categorical, epidemiological, imaging, psychopathological and treatment considerations

Chair: Marc Potenza, USA

Co-Chair: Florence Thibaut, France

S-14-001
Classification and clinical issues relating to hypersexuality

Marc Potenza, USA

S. Kraus

S-14-002
Sexual impulsivity, psychopathology and trauma: Gender-related differences

Galit Erez, Israel

S-14-003
Advances in pharmacological treatments for sex offenders

Florence Thibaut, France

S-14-004
Neurobiology of compulsive sexual behaviors

Valerie Voon, United Kingdom

T35: POSTTRAUMATIC STRESS: BASIC / CLINICAL
S-15

08:30–10:00

Posttraumatic Stress Disorder (PTSD) and gender

Chair: Hans-Jürgen Möller, German

Co-Chair: Victoria Valdez, Ecuador

S-15-001
Clinical issues: PTSD and gender violence

Victoria Valdez, Ecuador

S-15-002
Course and prognosis PTSD

Kayihan Oguz Karamustafa, Turkey

S-15-003
Biological aspects and PTSD

Soraya Seedat, South Africa

S-15-004
Genetics and PTSD

Sian Hermann, South Africa

Symposia / Preliminary Scientific Programme

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-16

08:30–10:00

The elephant in the room: The role of glial cells in psychiatric disorders

Chair: Sabina Berretta, USA

Co-Chair: Mikhail Pletnikov, USA

S-16-001

Psychiatric genetic risk factors in healthy and diseased astrocytes

Mikhail Pletnikov, USA

S-16-002

Glia-extracellular matrix interactions in the pathophysiology of schizophrenia and Bipolar Disorder (BD)

Sabina Berretta, USA

S-16-003

Abnormalities of glutamate transporter localization in severe mental illness

Robert McCullumsmith, USA

S-16-004

Evidence for neuroinflammation, gliosis and leaky brain in people with schizophrenia

Cyndi Shannon Weickert, Australia

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-17

08:30–10:00

Psychosis is disrespectful to diagnostic boundaries: Nosological and pathobiological implications of psychoses beyond the schizophrenia spectrum

Chair: John Waddington, Ireland

Co-Chair: Peter Buckley, USA

S-17-001

Reconciling the diversity of psychotic illness and dimensional concepts with current diagnostic algorithms

Rajiv Tandon, USA

S-17-002

Psychosis in major depressive disorder: Systematic comparisons with and beyond the schizophrenia spectrum

John Waddington, Ireland

S-17-003

Psychosis in Bipolar Disorder (BP): Genetics and relationships to paternal age

Peter Buckley, USA

J. Waddington

S-17-004

Post-stroke psychosis: Pathobiology and behavioral susceptibility

Eileen Joyce, United Kingdom

T49: SUICIDE: BASIC / CLINICAL

S-18

08:30–10:00

Epigenetic modification, effect of early life stress, and signaling mechanisms in suicide

Chair: Ghanshyam Pandey, USA

Co-Chair: Victoria Arango, USA

S-18-001

Impact of the early-life environment on the epigenetic regulation of the anterior cingulate gyrus

Gustavo Turecki, Canada

S-18-002

Expression and methylation of glucocorticoid receptors and FKBP5 in teenage and adult suicide

Ghanshyam Pandey, USA

S-18-003

Genome-wide epigenetic changes in suicide attempters

Jussi Jokinen, Sweden

S-18-004

5-HT1A receptor anti-apoptotic transduction pathways in suicide

Victoria Arango, USA

T11: DEPRESSION: BASIC / CLINICAL

S-19

08:30–10:00

Psychedelics: Mechanisms and applications in psychiatry

Chair: Tomas Palenicek, Czech Republic

Co-Chair: Franz X. Vollenweider, Switzerland

S-19-001

Role of 5-HT2A receptors in the mechanism of action of psilocybin and LSD and the treatment of affective disorders

Franz X. Vollenweider, Switzerland

S-19-002

The effect of psilocybin on brain connectivity and emotional processing in healthy volunteers

Tomas Palenicek, Czech Republic

S-19-003

Psilocybin for the treatment of depression

Robin Carhart-Harris, United Kingdom

Preliminary Scientific Programme / Symposia

S-19-004

Exploring the therapeutic potential of ayahuasca in the treatment of psychiatric disorders

Jordi Riba, Spain

T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC/CLINICAL

S-20

08:30–10:00

Affective and psychotic psychopathology from pregnancy to early adulthood: The dynamic developmental interplay between genes, structures and functions

Chair: Paolo Brambilla, Italy

Co-Chair: Michael Kaess, Germany

S-20-001

Can personality and parental care impact on brain development?

Paolo Brambilla, Italy

S-20-002

Neurodevelopmental trajectories and psychopathology in adolescents and adults who were born very preterm

Chiara Nosarti, United Kingdom

S-20-003

Grin2b mediates susceptibility to affective problems in children and adolescents

Maria Nobile, Italy

S-20-004

Corollary discharge auditory hallucinations and schizophrenia: A structural network analysis

Romy Hemze, Germany

T11: DEPRESSION: BASIC/CLINICAL

S-21

11:15–12:45

Measurement-based psychiatry: Toward rating scale-based assessments in the real world

Chair: Christoph U. Correll, USA

Co-Chair: Søren Dinesen Østergaard, Denmark

S-21-001

Measurement-based care psychiatry: Where are we at and where should we head?

Andrew A. Nierenberg, USA

S-21-002

Measurement-based care versus standard care for major depression: Conducting a success randomized controlled trial with blind raters

Christoph U. Correll, USA

S-21-003

The role for measurement-based care for bipolar disorder in current and future clinical practice

Eduard Vieta, Spain

S-21-004

PANSS-6: A new rating scale for both research and clinical care in schizophrenia

Søren Dinesen Østergaard, Denmark

T43: SCHIZOPHRENIA: BASIC/CLINICAL

S-22

11:15–12:45

Dissecting the shared and non-shared biological features in schizophrenia and autism spectrum disorder

Chair: Kenji Tsuchiya, Japan

Co-Chair: Manabu Makinodan, Japan

S-22-001

Comparative genetic analysis of autism spectrum disorder and schizophrenia: Focus on rare variants

Branko Aleksic, Japan

S-22-002

The genetic overlap between autism and schizophrenia: Focus on common variation

Jakob Grove, Denmark

S-22-003

Neurobiological findings in schizophrenia and autism spectrum disorder

Ryota Hashimoto, Japan

S-22-004

Neural-immune mechanisms in development and disease

Allison Bialas, USA

T9: COGNITIVE NEUROSCIENCE

S-23

11:15–12:45

Combining cognitive remediation with brain imaging techniques: Evidence for neural changes or neuroplasticity?

Chair: Martin Lepage, Canada

Co-Chair: Kamilla Miskowiak, Denmark

S-23-001

Neural markers and predictors of therapeutic change with cognitive enhancement therapy

Matcheri Keshavan, USA

Symposia / Preliminary Scientific Programme

S-23-002

Short-term working memory training for individuals with psychosis: Cognitive and neurophysiological effects

Christopher Bowie, Canada

S-23-003

Randomised trial of low support cognitive training for schizophrenia: Cortical and behavioural outcomes

Gary Donohoe, Ireland

S-23-004

SESAME: A brief intervention for memory in schizophrenia. Behavioral and imaging data

Martin Lepage, Canada

T4: ANXIETY DISORDERS: BASIC/CLINICAL

S-24

11:15–12:45

Serotonin and anxiety disorders: Recent evidences from neuroimaging studies

Chair: Eduard Maron, Estonia

Co-Chair: Tomas Furmark, Sweden

S-24-001

Serotonin system and panic disorder

Eduard Maron, Estonia

S-24-002

Serotonin system and social anxiety disorder

Tomas Furmark, Sweden

S-24-003

Serotonin system and obsessive-compulsive disorder

Oliver Pogarell, Germany

S-24-004

Serotonin regulation of anxiety neuronal network

Andreas Frick, Sweden

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-25

15:00–16:30

tDCS: From research to clinical practice

Chair: Emmanuel Poulet, France

Co-Chair: Jerome Brunelin, France

S-25-001

Translational research on tDCS: Data from a German multisite project

Frank Padberg, Germany

S-25-002

Combining tDCS with neuroimaging

Shirley Fecteau, Canada

S-25-003

Effects of tDCS on biological reactivity to stress and decision making

Jerome Brunelin, France

S-25-004

TDCS in mood disorders – ready to clinical practice? Results from recent phase-III randomised, controlled trials

Andre Brunoni, Brazil

T33: PHARMACOLOGY

S-26

15:00–16:30

Into novel drugs for depression

Chair: Erich Seifritz, Switzerland

S-26-001

Conceptual strategies of Big Pharma into innovation in psychiatric therapies: Future leads

Siegfried Kasper, Austria

S-26-002

Personalizing psychiatry treatment

Florian Holsboer, Germany

S-26-003

Psychedelic drugs and clinical markers as innovation road to psychopharmacotherapy

Franz X. Vollenweider, Switzerland

S-26-004

GHB as a candidate drug for stratified depression subtypes

Oliver G. Bosch, Switzerland

T43: SCHIZOPHRENIA: BASIC/CLINICAL

S-27

15:00–16:30

Beyond unitary models of psychosis: Confronting complex etiology and dimensionality

Chair: Mikhail Pletnikov, USA

Co-Chair: John Waddington, Ireland

S-27-001

Recognising the dimensionality of psychotic illness: Broadening the phenotype to the affective domain

Catherine Belzung, France

S-27-002

Addressing the translational challenge of etiological diversity: Complex gene-environment interactions in risk for psychosis

Mikhail Pletnikov, USA

Preliminary Scientific Programme / Symposia

S-27-003

Closing the translational gap between heritability and genetics: Complex gene-gene interactions in risk for psychosis

John Waddington, Ireland

S-27-004

Extending the strategy for translation: Human induced pluripotent stem cells

Kristen Brennand, USA

T11: DEPRESSION: BASIC/CLINICAL

S-28

15:00–16:30

Wake and sleep electroencephalogram provide biomarkers of depression

Chair: Axel Steiger, Germany

Co-Chair: Thorsten Mikoteit, Switzerland

S-28-001

Central and autonomous nervous system activity in the prediction of antidepressant treatment

Sebastian Olbrich, Switzerland

S-28-002

The value of prefrontal theta cordance of resting EEG in the prediction of antidepressant response

Martin Brunovsky, Czech Republic

S-28-003

Novel REM-sleep derived biomarkers of depression

Thorsten Mikoteit, Switzerland

S-28-004

sLORETA derived from REM sleep EEG as biomarkers for treatment response in depression after antidepressant medication

Marcel Pawlowski, Germany

T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC/CLINICAL

S-29

17:00–18:30

Autism spectrum disorders in adults – from the clinical phenotype to the underlying neurobiology – novel techniques such as phenotype-based genetic variants association studies, high field magnet resonance imaging and 3d brain organoids

Chair: Tanja Michel, Denmark

Co-Chair: Sophia Frangou, USA

S-29-001

On the outcome, time course and clinical presentation of autism in adults: A longitudinal study of clinical trajectories

Marlene Briciet Lauritsen, Denmark

S-29-002

Modulation of the autistic phenotypes in the broader fragile X gene family by accumulated common gene variants

Hannelore Ehrenreich, Germany

S-29-003

New insights from proteomics and nanotechnology-3 D brain organoids: A promising new tool for an vitro model for ASD

Tanja Michel, Denmark

S-29-004

The role of myelination in neurodevelopmental disorders

Sophia Frangou, USA

► Tuesday, 20 June 2017

T43: SCHIZOPHRENIA: BASIC/CLINICAL

S-30

08:30–10:00

Recent insights in schizophrenia physiopathology and treatments

Chair: Pierre-Michel Llorca, France

Co-Chair: Guillaume Fond, France

S-30-001

Bridging the gap between research and clinical practice: The development of a national network of schizophrenia expert centers

Guillaume Fond, France

S-30-002

Schizophrenia pathophysiology: Recent insights from neuroimaging on glutamatergic and neuroinflammatory mechanisms

Oliver Howes, United Kingdom

Symposia / Preliminary Scientific Programme

S-30-003

The influence of hormones on schizophrenia

Iris Sommer, The Netherlands

S-30-004

Novel adjunctive therapy approaches for inflammatory disturbances in psychiatric disorders

Michael Berk, Australia

T43: SCHIZOPHRENIA: BASIC/CLINICAL

S-31

08:30–10:00

Duration of untreated psychosis: From neuroimaging to clinical trials

Chair: John Kane, USA

Co-Chair: Erika Jaaskelainen, Finland

S-31-001

Is DUP a moderator of effectiveness with comprehensive specialty care in first episode schizophrenia?

John Kane, USA

S-31-002

The impact of DUP on short and long term outcomes in schizophrenia

Erika Jaaskelainen, Finland

S-31-003

Is there a relationship between DUP and brain structure?

Aristotle Voineskos, Canada

S-31-004

MRI resting state functional connectivity and DUP

Deepak Sarpal, USA

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-32

08:30–10:00

New perspectives on transcranial magnetic stimulation in psychiatric disorders

Chair: Shinsuke Kito, Japan

Co-Chair: Motoaki Nakamura, Japan

S-32-001

Transcranial magnetic stimulation in the treatment of bipolar depression

Shinsuke Kito, Japan

S-32-002

Clinical and neurobiological effects of Quadripulse Stimulation (QPS) and Theta Burst Stimulation (TBS) in Mood Disorders (MD)

Motoaki Nakamura, Japan

S-32-003

Neurophysiological correlates of various transcranial magnetic stimulation paradigms in patients with psychiatric disorders: In search of novel biomarkers

Yoshihiro Noda, Japan

S-32-004

Combination of computerized cognitive remediation and transcranial magnetic stimulation

Akihiro Takamiya, Japan

T11: DEPRESSION: BASIC/CLINICAL

S-33

08:30–10:00

Epigenetic biomarkers for the diagnosis of mood disorders

Chair: Tetsuro Ohmori, Japan

Co-Chair: Lourdes Fañanás, Spain

S-33-001

DNA methylation profiles of the Brain-derived Neurotrophic Factor (BDNF) gene as a potent diagnostic biomarker in major depression

Manabu Fuchikami, Japan

S-33-002

Antenatal prediction of postpartum depression with blood DNA methylation biomarkers

Zachary Kaminsky, USA

S-33-003

Blood diagnostic biomarkers for major depressive disorder using multiplex DNA methylation profiles

Shusuke Numata, Japan

S-33-004

Differential methylation and variable methylation in depression: A genome-wide analysis of monozygotic twins

Aldo Cordova-Palomera, Spain

T40: PSYCHOPATHOLOGY

S-34

08:30–10:00

Sex hormones and their wide-ranging effects on psychopathology

Chair: Andrea Gogos, Australia

Co-Chair: Mark Geyer, USA

S-34-001

Estrogen, raloxifene and schizophrenia

Cyndi Shannon Weickert, Australia

Preliminary Scientific Programme / Symposia

S-34-002

Cortical gene expression changes underlying estrogen's effect in schizophrenia

Andrea Gogos, Australia

S-34-003

17 β -estradiol effects on psychosis-like attentional abnormalities in rats

Ina Weiner, Israel

S-34-004

Sex differences in depression: The role of neuroestrogens

Christina Dalla, Greece

T27: OBSESSIVE-COMPULSIVE DISORDERS: BASIC / CLINICAL

S-35

08:30–10:00

New insights into the neurobiology and treatment aspects of obsessive compulsive disorder comorbid with schizophrenia and bipolar affective disorder

Chair: E. Mohandas, India

Co-Chair: Narayan R. Mutalik, India

S-35-001

Neurobiology of obsessive compulsive disorder comorbid with schizophrenia

Narayan R. Mutalik, India

S-35-002

Evidence based management of obsessive compulsive disorder comorbid with schizophrenia

Firoz Kazhungil, India

S-35-003

Neurobiology of obsessive compulsive disorder comorbid with bipolar disorder

Rajan Nishanth Jayarajan, Australia

S-35-004

Recent updates in the management of obsessive compulsive disorder comorbid with Bipolar Disorder (BP)

Pawan Sharma, Nepal

T9: COGNITIVE NEUROSCIENCE

S-36 SYMPOSIUM

11:15–12:45

The role of the nucleus accumbens in psychiatry

Chair: Jens Kuhn, Germany

Co-Chair: Leonhard Schilbach, Germany

S-36-001

The anatomy of the nucleus accumbens

Ioannis Mavridis, Greece

S-36-002

The role of nucleus accumbens in social cognition

Leonhard Schilbach, Germany

S-36-003

The role of nucleus accumbens in impulsivity

Valerie Voon, United Kingdom

S-36-004

Deep brain stimulation of the nucleus accumbens

Sina Kohl, Germany

T11: DEPRESSION: BASIC / CLINICAL

S-37

11:15–12:45

Neurobiologic imaging studies of mood disorders, neurogenetics and antidepressant action with positron emission tomography

Chair: J. John Mann, USA

Co-Chair: Gitte Moos Knudsen, Denmark

S-37-001

Familial transmission of 5-HT_{1A} autoreceptor up-regulation: An impaired serotonergic endophenotype in mood disorders

J. John Mann, USA

S-37-002

Molecular neuroimaging and genetics

Gitte Moos Knudsen, Denmark

S-37-003

cAMP Cascade in major depressive disorder: Downregulation in unmedicated patients and normalization with treatment

Robert Innis, USA

S-37-004

Predictiveness of peripheral and clinical markers for PET measurement of inflammation and monoamine oxidase: Implications for biomarker development

Jeffrey Meyer, Canada

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-38

11:15–12:45

Treatment resistant schizophrenia: Definitions, psychobiology and clinical treatment

Chair: John Kane, USA

Co-Chair: Ofer Agid, Canada

S-38-001

Methodological issues in clinical trial designs for TRS

John Kane, USA

Symposia / Preliminary Scientific Programme

S-38-002

A longitudinal perspective on the evolution of treatment resistance

Ofer Agid, Canada

S-38-003

The biology of treatment resistance

Oliver Howes, United Kingdom

S-38-004

Definitions and epidemiology of treatment resistance

Christoph U. Correll, USA

T1: ADDICTIVE DISORDERS

S-39

15:00–16:30

Current research on the use of cannabinoids

Chair: Aviv Weinstein, Israel

Co-Chair: Amine Benyamina, France

S-39-001

Cannabis use disorder and its effects on cognitive function

Valerie Curran, United Kingdom

S-39-002

The relationship between cannabis and psychosis

Deepak Cyril D'Souza, USA

S-39-003

The genetics of cannabis use disorder

Amine Benyamina, France

S-39-004

The effects of chronic use of synthetic cannabinoids on executive brain function

Aviv Weinstein, Israel

T10: DEMENTIA: BASIC / CLINICAL

S-40

15:00–16:30

Alzheimer's Disease (AD) pathophysiology, prevention and treatment strategies: Where we stand and where we go?

Chair: Jerzy Leszek, Poland

Co-Chair: Ramon Cacabelos, Spain

S-40-001

Pharmacogenetics of cerebrovascular phenotypes of risk in dementia

Ramon Cacabelos, Spain

S-40-002

Insulin resistance in neurodegeneration: The role of p53/miRNA/SIRT1 axis

Kazimierz Gasiorowski, Poland

S-40-003

Alzheimer drug discovery: Targeting synaptic glutamate signaling

Markku Kurkinen, USA

S-40-004

Nanotechnology for early detection and treatment of Alzheimer's Disease (AD): Where we stand and where we go?

Jerzy Leszek, Poland

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-41

15:00–16:30

Electroconvulsive therapy for depression – optimising treatment and maintaining recovery

Chair: Declan McLoughlin, Ireland

Co-Chair: Pascal Sienaert, Belgium

S-41-001

The KEEP-WELL Trial: Ketamine for depression relapse prevention following ECT (NCT02414932)

Declan McLoughlin, Ireland

S-41-002

Immediate and long-term outcomes for Brief-pulse (BP) vs Ultrabrief-pulse (UBP) high-dose unilateral ECT: The ResPECT trials' experience

Pascal Sienaert, Belgium

H.-P. Spaans, E. Verwijk, F. Bouckaert

S-41-003

Pre- and post-ECT cognitive performance as predictors for outcome and relapse in depression (NTR1304)

Esmée Verwijk, The Netherlands

S-41-004

The PRIDE Trial – Prolonging remission in depressed elderly (NCT01028508): Results from the randomised phase

Charles Kellner, USA

T22: MOLECULAR NEUROBIOLOGY

S-42

17:00–18:30

Neuroepigenetic approaches to assess disease risk, mechanism and treatment

Chair: Alfonso Buil, Denmark

Co-Chair: Jonathan Mill, United Kingdom

S-42-001

CACNA1C hypermethylation associated with Bipolar Disorder (BD)

Anna Starnawska, Denmark

D. Demontis, A. Pen, A. Hedemand, A. L. Nielsen,

Preliminary Scientific Programme / Symposia

*N. H. Staunstrup, J. Grove, T. D. Als, A. Jarram,
N. L. O'Brien, O. Mors, A. McQuillin, A. D. Børghlum*

S-42-002

Epigenomic trajectories across human brain development: Relevance for schizophrenia and other neurodevelopmental disorders

Jonathan Mill, United Kingdom

S-42-003

Neonatal epigenetic profiling in Danish twins discordant for psychiatric disorder

Shantel Weinsheimer, Denmark

*C. Hansen, A. Starnawska, T. Sparsø, W. Mazin,
M. Bertalan, J. Grauholm, M. Bækvad-Hansen, A. Buil,
D. M. Hougaard, T. M. Werge*

S-42-004

Epigenetics in schizophrenia and association with anti-psychotic response to clozapine

Marta Bosia, Italy

► Wednesday, 21 June 2017

T2: ANTIDEPRESSANTS: BASIC / CLINICAL

S-43

08:30–10:00

Novel approaches in mechanisms of action of antidepressant treatment

Chair: Rainer Rupprecht, Germany

S-43-001

Signal transduction in membranes as mechanism of action of antidepressants

Mark Rasenick, USA

S-43-002

Cytoskeleton as target for antidepressants

Massimiliano Bianchi, Ireland

S-43-003

Biomarkers during antidepressant treatment

Thomas Baghai, Germany

S-43-004

Relevance of P-Glycoprotein and blood brain barrier for antidepressant treatment

Carmine Pariante, United Kingdom

T17: GENETICS

S-44

08:30–10:00

Cannabinoid Receptor (CBR) gene variations in neuropsychiatric disorders

Chair: Hiroki Ishiguro, Japan

Co-Chair: Emmanuel Onaivi, USA

S-44-001

Environmental stressors induce psychosis based on genetic variation of CB2Rs

Hiroki Ishiguro, Japan

S-44-002

ECB system alteration in an animal model of autism spectrum disorders

Eugene Dennis, USA

S-44-003

Species differences in CBR genes

Qing-Rong Liu, USA

S-44-004

CBR genetics: From mice to human subjects

Emmanuel Onaivi, USA

T1: ADDICTIVE DISORDERS

S-45

08:30–10:00

Behavioral addictions: Diagnosis, co-morbidity and neurobiology

Chair: Michel Lejoyeux, France

Co-Chair: Aviv Weinstein, Israel

S-45-001

Internet gaming disorder- addiction, co-morbidity and the brain

Aviv Weinstein, Israel

S-45-002

Neuroimaging evidence for considering hypersexuality as an addiction

Florence Thibaut, France

S-45-003

New data on phenomenology and psychiatric comorbidity of compulsive buying

Michel Lejoyeux, France

S-45-004

The genetic background of gambling behavior

Zsolt Demetrovics, Hungary

*E. Kótyuk, A. Vereczkei, R. Urbán, A. Eisinger, A. Magi,
G. Kökönyei, A. Veres-Székely, Á. Gyollai, K. Blum,
M. Sasvári-Székely, C. Barta*

Symposia / Preliminary Scientific Programme

T50: VIOLENCE: BASIC / CLINICAL

S-46

08:30–10:00

Neurobiology and psychopharmacology of aggressive behaviour: Where are we?

Chair: Stefano Comai, Italy

Co-Chair: Gabriella Gobbi, Canada

S-46-001

Neurobiology and biomarkers of aggression

Stefano Comai, Italy

S-46-002

Clinical management of aggression in childhood and adolescence

Florian D. Zepf, Australia

S-46-003

Drug abuse/dependence and aggressive behaviour

Gabriella Gobbi, Canada

S-46-004

Epilepsy, antiepileptic drugs and aggression

Martin J. Brodie, United Kingdom

T11: DEPRESSION: BASIC / CLINICAL

S-47

08:30–10:00

Catecholamines, anhedonia and depression

Chair: Jose Luis Ayuso, Spain

Co-Chair: Victoria Valdez, Ecuador

S-47-001

Catecholamines, reward circuits and depression

Gregor Hasler, Switzerland

S-47-002

Positive affects and depression

Jorge Tellez-Vargas, Colombia

S-47-003

Anhedonia and suicide behavior

Maurizio Pompili, Italy

S-47-004

Exploring the role of proinflammatory cytokines in anhedonia

Ruby Castilla-Puentes, USA

T32: PHARMACOGENETICS

S-48

11:15–12:45

Pharmacogenetics of drug defense and neuroprotection: From the Neandertal to the modern humans

Chair: Julia Stingl, Germany

Co-Chair: Magnus Ingelman-Sundberg, Sweden

S-48-001

The evolutionary aspect of trait biomarkers in drug metabolism and neuroprotection

Magnus Ingelman-Sundberg, Sweden

S-48-002

Pharmacogenetic polymorphisms on behavioral and structural brain phenotypes uncovered by neuroimaging data

Roberto Viviani, Austria

S-48-003

Prevention of drug toxicity to the brain: The vulnerable brain and ADRs of nervous system disorders

Julia Stingl, Germany

S-48-004

Pharmacogenetic factors in neuroprotection during neurodevelopment

Karim Barakat, Germany

T11: DEPRESSION: BASIC / CLINICAL

S-49

11:15–12:46

Evidence-based guidelines for treatment of major depressive disorder: Contrasting views across the world

Chair: Roumen Milev, Canada

Co-Chair: Allan Young, United Kingdom

S-49-001

A subequatorial view: The new RANZCP guidelines

Gin Malhi, Australia

S-49-002

The evolution of the CANMAT guidelines

Raymond Lam, Canada

S-49-003

The view from the UK: BAP guidelines for Mood Disorders (MD)

Allan Young, United Kingdom

S-49-004

Even the best guidelines don't work unless they are implemented

Sagar Parikh, USA

Preliminary Scientific Programme / Symposia

T6: BIPOLAR DISORDERS: BASIC/CLINICAL

S-50

11:15–12:45

Real time assessment of psychopathology and behavior in Bipolar Disorder (BP) using e-mental health technologies

Chair: *Lars Kessing, Denmark*

Co-Chair: *Michael Bauer, Germany*

S-50-001

Mood instability and Bipolar Disorder (BD): Deriving useful biosignatures from multidimensional, time stamped, streamed data

John Geddes, United Kingdom

S-50-002

Smartphone based ambulatory assessment of early warning signs in Bipolar Disorder (BP)

Michael Bauer, Germany

S-50-003

Smartphones as objective electronic behavioral biomarkers of illness activity in Bipolar Disorder (BP)

Lars Kessing, Denmark

S-50-004

Voice recognition as objective electronic behavioral biomarkers of illness activity in Bipolar Disorder (BP)

Maria Fauerholt-Jepsen, Denmark

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-51

15:00–16:30

Advances in biomarker development for neurostimulation

Chair: *Paul Croarkin, USA*

Co-Chair: *Motoaki Nakamura, Japan*

S-51-001

Stimulation-induced neuroplasticity of prefrontal cortex in adult autism spectrum disorder

Motoaki Nakamura, Japan

S-51-002

Glutamatergic biomarker development for repetitive transcranial magnetic stimulation

Paul Croarkin, USA

S-51-003

Neurocognitive effects of major depressive disorder and neurostimulation therapies

Shawn McClintock, USA

S-51-004

Predicting remission of suicidal ideation following Magnetic Seizure Therapy (MST) in patients with treatment-resistant depression

Zafiris J. Daskalakis, Canada

T3: ANTIPSYCHOTICS: BASIC/CLINICAL

S-52

15:00–16:30

The G protein coupled receptors as a target for psychotropic drugs

Chair: *Andrzej Pilc, Poland*

Co-Chair: *Jeffrey P. Conn, USA*

S-52-001

Positive allosteric modulators of GPCRs as a novel treatment for schizophrenia

Jeffrey P. Conn, USA

S-52-002

The mGlu5 receptor imaging in schizophrenia and depression

Gregor Hasler, Switzerland

S-52-003

The mGlu2/3 receptor as a novel therapeutic target for treatment-resistant depression

Shigeyuki Chaki, Japan

S-52-004

The allosteric modulation of group III mGlu receptors as target for antipsychotic or antidepressant drugs

Andrzej Pilc, Poland

T49: SUICIDE: BASIC/CLINICAL

S-53

15:00–16:30

Suicidal behavior: Neurobiological and genetic determinants

Chair: *Yogesh Dwivedi, USA*

S-53-001

Epigenetic modifications in brain of suicide individuals: Focus on global and site-specific changes in 5-hydroxymethylcytosine

Gustavo Turecki, Canada

S-53-002

Genetics of intermediate phenotypes for suicidal behavior: Focus on impulsivity and aggression

Dan Rujescu, Germany

S-53-003

Toxoplasma gondii seropositivity and suicidal behavior

Teodor Postalache, USA

Symposia / Preliminary Scientific Programme

S-53-004

Non-coding RNAs: Novel epigenetic regulators in suicidal behavior

Yogesh Dwivedi, USA

T51: PSYCHOPHARMACOLOGY

S-54

17:00–18:30

Lithium as a neuroprotective agent: When and how?

Chair: Galila Agam, Israel

Co-Chair: Changlian Zhu, People's Republic of China

S-54-001

In vivo lithium-induced augments mitochondrial function, reduces neuroinflammation and increases autophagy

Galila Agam, Israel

S-54-002

Lithium as a novel approach to treat developing brain injury

Changlian Zhu, China, People's Republic of

S-54-003

Hui Zhang, USA

S-54-004

Francoise Croute, France

T23: MOOD STABILISERS: BASIC/CLINICAL

S-55

17:00–18:30

Rediscovering Lithium

Chair: David Taylor, United Kingdom

Co-Chair: Jonathan Meyer, USA

S-55-001

The evidence for Lithium's antisuicide properties and impact on mortality

Jimmi Nielsen, Denmark

S-55-002

The evidence for Lithium's neuroprotective properties

Barrat Luft, United Kingdom

S-55-003

What is the risk for end stage renal disease with Lithium: A sophisticated review

Ursula Werneke, Sweden

M. Ott, E. Salander Renberg, B. Stegmayr

S-55-004

An update on assessing and managing Lithium's renal effects

Jonathan Meyer, USA

► Thursday, 22 June 2017

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-56

08:30–10:00

Clinical effects and neural mechanisms of electroconvulsive therapy in major depression and schizophrenia

Chair: Robert Christian Wolf, Germany

Co-Chair: Philipp Thomann, Germany

S-56-001

ECT in major depression and schizophrenia: Indications and clinical effects

Dusan Hirjak, Germany

S-56-002

Effects of ECT on brain structure and function: Lessons from major depressive disorder

Robert Christian Wolf, Germany

S-56-003

ECT-related effects on regional brain volume and structural networks in patients with schizophrenia and major depressive disorder

Philipp Thomann, Germany

S-56-004

Modulation of intrinsic network connectivity by ECT in patients with schizophrenia and major depressive disorder

Fabio Sambataro, Italy

T6: BIPOLAR DISORDERS: BASIC/CLINICAL

S-57

08:30–10:00

Causes and consequences of inflammation in Bipolar Disorder (BP)

Chair: Lars Kessing, Denmark

Co-Chair: Flavio Kapczinski, Brazil

S-57-001

Peripheral inflammation in Bipolar Disorder (BP): Trait and state related alterations

Klaus Munkholm, Denmark

S-57-002

Targeting mitochondrial inflammation in Bipolar Disorder (BP)

Ana Andrezza, Canada

S-57-003

Relationships between inflammation, elevated body mass index, and depressive relapse in Bipolar Disorder (BP)

David Bond, USA

Preliminary Scientific Programme / Symposia

S-57-004

Genetic and central nervous system aspects of immune dysregulation in Bipolar Disorder (BP)

Bartholomeus Haarman, The Netherlands

T51: NEURODEGENERATIVE DISORDERS
S-58

08:30–10:00

Novel therapeutics for neurodegenerative disorders

Chair: Ramon Cacabelos García, Spain

S-58-001

ASS234, as a new multi-target directed propargylamine for Alzheimer's Disease (AD) therapy

José Marco-Contelles, Spain

S-58-002

EB101 immunotherapy against amyloid: A promising strategy for treating Alzheimer's Disease (AD)

Ivan Carrera, Spain

S-58-003

The Intelligent Pharmacogenetic Card (PGx-iCard) for neuropsychiatric disorders

Juan C. Carril, Spain

S-58-004

Neuroprotective effects of Atremorine in Cerebral Ischemia and Parkinson disease-related models

Javier Egea, Spain

S-58-005

Basic and clinical studies with E-PodoFavalin-15999 (Atremorine®) in Parkinson's Disease: Selective dopaminergic neuroprotection and pharmacogenetics

Ramon Cacabelos, Spain

T22: MOLECULAR NEUROBIOLOGY
S-59

08:30–10:00

The relevance of Neuregulin1-ErbB4 signaling for neuropsychiatric pathomechanisms: Converging insights from mouse genetics, physiology, and human studies

Chair: Peter Falkai, Germany

Co-Chair: Moritz Rossner, Germany

S-59-001

The relevance of Neuregulin1-ErbB4 signaling for neuropsychiatric pathomechanisms: Insights from human studies

Cyndi Shannon Weickert, Australia

S-59-002

Neuregulin1-ErbB4 signaling: Integration at the network level

Beatriz Rico, United Kingdom

S-59-003

The relevance of Neuregulin1-ErbB4: Insights from mouse physiological analyses

Andrés Buonanno, USA

S-59-004

Neuregulin1-ErbB4 signaling: Insights from mouse genetics

Markus Schwab, Germany

T22: MOLECULAR NEUROBIOLOGY
S-60

08:30–10:00

Multi-omics and psychiatry: The missing molecular link

Chair: Michaela Filiou, Germany

Co-Chair: Anthony Zannas, Germany

S-60-001

Epigenomics of stress-related disorders: Current evidence, limitations, and future directions

Anthony Zannas, Germany

S-60-002

From proteomics to biological mechanisms involved in schizophrenia

Daniel Martins de Souza, Brazil

S-60-003

Multi-omics driven discovery of pharmacological targets for stress-related disorders

Michaela Filiou, Germany

S-60-004

Role of CYP2C19 in major depressive disorder – translational study

Marin Jukic, Sweden

T49: SUICIDE: BASIC / CLINICAL
S-61

08:30–10:00

Suicide: Aspects that burn

Chair: Konstantinos Fountoulakis, Greece

Co-Chair: Dina Popovic, Spain

S-61-001

Genetic basis of suicidal behaviour

Alessandro Serretti, Italy

S-61-002

Mixed features and suicidality: Is DSM 5 wrong?

Dina Popovic, Spain

Symposia / Preliminary Scientific Programme

S-61-003

How does clinical prediction of suicidality affect our daily clinical practice?

Mark Weiser, Israel

M. Davidson

S-61-004

Suicidality and overlapping geographical maps: Spurious correlations or cues for an underlying biological substrate?

Konstantinos Fountoulakis, Greece

T49: SUICIDE: BASIC / CLINICAL

S-62

11:00–12:30

Innovative approaches in suicide research

Chair: Philippe Courtet, France

Co-Chair: Sidney Kennedy, Canada

S-62-001

Initiative for research network

Sidney Kennedy, Canada

S-62-002

Neurosciences based phenomenology of suicidal behaviour

Philippe Courtet, France

S-62-003

MeMind project: Ambulatory assessment in suicide behaviour. Do different things to expect different results?

Enrique Baca Garcia, Spain

S-62-004

The use of machine learning and big data to predict suicide

Michael Berk, Australia

T33: PHARMACOLOGY

S-63

11:00–12:30

Atypical neurotransmitters in psychiatry: Relevance for future therapeutics

Chair: Gregers Wegener, Denmark

Co-Chair: Sâmia Joca, Brazil

S-63-001

Nitric oxide signalling in psychiatric disorders: Evidence from Gene x Environment x Development (GxExD) studies

Gregers Wegener, Denmark

S-63-002

ATP and NO interaction in stress models of depression

Sâmia Joca, Brazil

S-63-003

The endocannabinoid and endovanilloid system in stress-coping responses

Fabricio Moreira, Brazil

S-63-004

Neurotrophins and psychiatric disorders

Eero Castrén, Finland

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-64

11:00–12:30

Operationalizing the dysconnection syndrome: Translational approaches reveal brain network dysfunction in schizophrenia

Chair: Bernat Kocsis, USA

Co-Chair: Vaibhav Diwadkar, USA

S-64-001

Dysconnection in rodent models of schizophrenia: Directed connectivity analyses of frequency-tagged oscillatory coupling of frontal-hippocampal signals

Bernat Kocsis, USA

S-64-002

Ketamine disrupts the functional state of corticothalamic systems: A mechanistic model of first-episode psychosis

Didier Pinault, France

S-64-003

Structural and functional brain dysconnectivity predating the onset of psychosis

Stefan Borgwardt, Switzerland

S-64-004

The dynamics of the functional “dysconnectome” in schizophrenia: Network modeling of in vivo fMRI signals

Vaibhav Diwadkar, USA

T24: NEUROPATHOLOGY

S-65

11:00–12:30

Cell-type specific epigenetic, proteomic and gene expression signatures in schizophrenia: New findings from post-mortem investigations

Chair: Peter Falkai, Germany

Co-Chair: Andrea Schmitt, Germany

S-65-001

Alteration of genome-wide gene expression in hippocampal CA4 pyramidal neurons in schizophrenia

Andrea Schmitt, Germany

Preliminary Scientific Programme / Symposia

S-65-002

Is the energy dysfunction observed in schizophrenia brains being originated in oligodendrocytes?

Daniel Martins de Souza, Brazil

S-65-003

Integrated analysis of cell-type specific epigenome-wide methylation changes in schizophrenia brains

Theo Kraus, Germany

A. Schmitt, J. Spanner, P. Falkai, A. Giese

S-65-004

Epigenetic signatures in the brain of schizophrenia patients

Andre Fischer, Germany

T33: PHARMACOLOGY

S-66

11:00–12:30

NMDA receptor antagonists in psychiatry

Chair: Peter Gass, Germany

Co-Chair: Gerard Sanacora, USA

S-66-001

Glutamatergic mechanisms in schizophrenia: Focus on genetics

Dan Rujescu, Germany

S-66-002

Insight into Ketamine's effect via cross-species translational neuroimaging

Oliver Grimm, Switzerland

S-66-003

Molecular and cellular determinants of the pleiotropic effects of NMDA receptor antagonists

Dragos Inta, Germany

S-66-004

Antidepressant effects of NMDA receptor targeting drugs

Gerard Sanacora, USA

T11: DEPRESSION: BASIC / CLINICAL

S-67

11:00–12:30

Spectrum of Mood Disorders (MD): Where is the place for mixed states?

Chair: Trisha Suppes, USA

S-67-001

Mood Disorders (MD) and mixed states: Evolution in diagnostic classification

Roger McIntyre, Canada

S-67-002

Bipolar mixed states: Review of clinical presentation, treatment and outcomes

Mark Frye, USA

S-67-003

Major depressive disorder with mixed features: Epidemiology, clinical characteristics and prognosis

Allan Young, United Kingdom

S-67-004

Major depressive disorder with mixed features: Review of current treatment options

Trisha Suppes, USA

T25: NEUROIMAGING: GENETIC, FUNCTIONAL, STRUCTURAL

S-68

15:00–16:30

Dynamical brain: How brain complexity changes with aging and mental illness?

Chair: Chih-Chieh Yang, USA

S-68-001

Dynamical analysis of brain activity: A new research dimension

Chih-Chieh Yang, USA

S-68-002

Assessment of neurophysiological changes with electroconvulsive therapy in mental disorders using nonlinear approach

Ryoko Okazaki, Japan

S-68-003

Increasing signal variability during development and its relevance to autism spectrum disorders

Tetsuya Takahashi, Japan

S-68-004

Neurophysiological basis of creativity in healthy elderly people using nonlinear approach

Kanji Ueno, Japan

Symposia / Preliminary Scientific Programme

T19: INFLAMMATION PSYCHIATRY

S-69

15:00–16:30

Increased intestinal permeability and bacterial translocation in neuro-psychiatric disorders

Chair: Michael Maes, Australia

Co-Chair: Yolanda Sanz, Spain

S-69-001

Increased intestinal permeability and bacterial translocation in depression and chronic fatigue syndrome

Michael Maes, Thailand

S-69-002

Increased intestinal permeability and bacterial translocation in chronic stress animal models

Javier Caso, Spain

S-69-003

Increased intestinal permeability and bacterial translocation in neurodevelopmental disorders

Yolanda Sanz, Spain

S-69-004

Increased intestinal permeability and bacterial translocation in schizophrenia

Emily Severance, USA

T26: NEUROPHYSIOLOGY

S-70

15:00–16:30

Current use of EEG-based techniques in psychiatry

Chair: Martijn Arns, The Netherlands

Co-Chair: Adam Wichniak, Poland

S-70-001

Epilepsy spectrum disorders and episodic psychiatric symptoms

Nash N. Boutros, USA

S-70-002

Results of the international multi-center iSPOT-A study in ADHD: EEG predictors of treatment outcome to methylphenidate

Martijn Arns, The Netherlands

S-70-003

Did the No-Go P300 component help to predict relapse in recently detoxified alcoholic patients?

Salvatore Campanella, Belgium

S-70-004

Polysomnographic measures of sleep in psychiatry: Implications for diagnosis and treatment

Adam Wichniak, Poland

T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC / CLINICAL

S-71

15:00–16:30

Sex-specific neuroendocrinological findings in conduct disorder

Chair: Sabine Herpertz, Germany

Co-Chair: Christine Freitag, Germany

S-71-001

The brain oxytocin system in intermale and female aggression in rodents

Trynke DeJong, Germany

I. Neumann

S-71-002

Sex-specific differences in oxytocin effects on the brain's salience circuit

Ruth Schmitt, Germany

S-71-003

Sex-specific differences and the effects of puberty on emotional processing in adolescents with and without conduct disorder

Kerstin Konrad, Germany

S-71-004

The role of basal and reactive steroid hormones and neuropeptides in female conduct disorder

Christine Freitag, Germany

A. Martinelli, K. Ackermann, A. Bernhard, FemNAT-CD study team

T6: BIPOLAR DISORDERS: BASIC / CLINICAL

S-72

15:00–16:30

Socio-demographic and clinical differences between Bipolar I and II Disorder (BP) and implications for treatment

Chair: Carlo Altamura, Italy

Co-Chair: Bernardo Dell'Osso, Italy

S-72-001

Bipolar I vs II Disorder (BP): Characterization of socio-demographic and clinical variables in Italian and American samples

Bernardo Dell'Osso, Italy

S-72-002

Clinical implications of predominant polarity and polarity index in Bipolar Disorders (BP)

Eduard Vieta, Spain

Preliminary Scientific Programme / Symposia, Workshops

S-72-003

Epidemiology and clinical correlates of suicide and suicide attempts in Bipolar Disorders (BP)

Maurizio Pompili, Italy

S-72-004

Do we have evidence for differentiating pharmacological treatment of Bipolar I from Bipolar II Disorder (BP)?

Terence Ketter, USA

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-73

15:00–16:30

Neuropathologic implication of abnormal cortico-basal ganglia connectivity in schizophrenia hallucination and its models

Chair: Hiroyuki Nawa, Japan

S-73-001

Neuropathologic implication of pallidal hyperactivity in the auditory abnormality of schizophrenia animal models

Hiroyuki Nawa, Japan

S-73-002

The rat ketamine model of schizophrenia shows aberrant oscillatory activity in the cortico-basal ganglia circuit

Miguel Valencia, Spain

S-73-003

Excess striatal dopamine and aberrant information processing model of psychosis in schizophrenia

Jong Yoon, USA

S-73-004

Subcortical modulation in auditory processing and auditory hallucinations

Toshikazu Ikuta, USA

Workshops

► **Sunday, 18 June 2017**

T51: NATIONAL INITIATIVES

WS-01

08:30–10:00

Initiatives from the Spanish Society of Biological Psychiatry: From evidence to experience

Chair: Miquel Bernardo, Spain

Co-Chair: Ana Gonzalez Pinto, Spain

WS-01-001

Agitation consensus

Eduard Vieta, Spain

WS-01-002

ECT consensus

Mikel Urretavizcaya, Spain

WS-01-003

Clinical guidelines for adult patients with a severe mental disorder and a comorbid substance use

Luis San, Spain

T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC / CLINICAL

WS-02

10:15–11:45

New investigations on the relationship between working memory and ADHD

Chair: Joseph Biederman, USA

WS-02-001

Clinical correlates of working memory deficits in youth with and without ADHD

Ronna Fried, USA

WS-02-002

Are working memory deficits and ADHD dissociable?: An fMRI study

Joseph Biederman, USA

WS-02-003

Reduced prefrontal efficiency for visuospatial working memory in attention-deficit/hyperactivity disorder

Jeffrey Newcorn, USA

WS-02-004

Working memory deficits in a prenatal nicotine exposure mouse model

Pradeep Bhide, USA

Workshops / Preliminary Scientific Programme

► Monday, 19 June 2017

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

WS-03

11:15–12:45

Current status of electroconvulsive therapy in the treatment of major psychiatric disorders

Chair: Yong-Sik Kim, Republic of Korea
Co-Chair: Pascal Sienaert, Belgium

WS-03-001

Current status on efficacy of ECT

Hans Mørch Jensen, Denmark

WS-03-002

Mechanism of ECT focused on psychosis

Ung-Gu Kang, Republic of Korea

WS-03-003

ECT for the treatment resistant psychosis

In-Won Chung, Republic of Korea

WS-03-004

ECT in catatonia

Pascal Sienaert, Belgium

T11: DEPRESSION: BASIC / CLINICAL

WS-04

15:00–16:30

Rethinking depression in the Century XXI: Where are we now in biological psychiatry?

Chair: Victoria Valdez, Argentina
Co-Chair: Adriana Rivetti, Argentina

WS-04-001

Is depression an inflammatory-metabolic disease?

Andrea Marquez Lopez Mato, Argentina

WS-04-002

Genetics risk variants for major depressive disorder

Alejo Corrales, Argentina

WS-04-003

Rethinking depression in the Century XXI

Victoria Valdez, Argentina

WS-04-004

Serotonergic hypothesis of depression: Is still up-to-date?

Adriana Rivetti, Argentina

► Tuesday, 20 June 2017

T43: SCHIZOPHRENIA: BASIC / CLINICAL

WS-05

08:30–10:00

Gesture as window to psychosis pathobiology: From aberrant body experience to social interaction

Chair: Sebastian Walther, Switzerland
Co-Chair: Vijay Mittal, USA

WS-05-001

Schizophrenia in the flesh: Empirical studies of anomalous bodily self experiences

So-Hee Park, USA

WS-05-002

Impaired gesture performance in schizophrenia: Neurobiology and clinical consequences

Sebastian Walther, Switzerland

WS-05-003

The neural correlates of natural social-communicative perception processes in patients with schizophrenia: Understanding, recognition and interpretation of verbal and non-verbal information

Benjamin Straube, Germany

WS-05-004

What can gesture-speech mismatch tell us about pathophysiology underlying psychosis-risk syndromes?

Vijay Mittal, USA

T49: SUICIDE: BASIC / CLINICAL

WS-06

11:15–12:45

Neurobiology of suicidal behaviour

Chair: Leo Sher, USA
Co-Chair: Zoltan Rihmer, Hungary

WS-06-001

Testosterone and suicidal behavior in men and women

Leo Sher, USA

WS-06-002

Suicide in men: Clinical and biological correlates

Zoltan Rihmer, Hungary

WS-06-003

Neuroinflammatory biomarkers of suicidal behavior

Jussi Jokinen, Sweden

WS-06-004

Endophenotypes of suicidal behavior for genetic research

Xenia Gonda, Hungary

Preliminary Scientific Programme / Workshops

T11: DEPRESSION: BASIC/CLINICAL

WS-07

15:00–16:30

Merging evidence and clinical practice in management of depression: The CANMAT experience

Chair: *Sidney Kennedy, Canada*

Co-Chair: *Roumen Milev, Canada*

WS-07-001

Guidelines for Pharmacological Management of Depression

Raymond Lam, Canada

WS-07-002

Making Effective Guidelines: Examples of Evidence-based Dissemination and Implementation Strategies

Sagar Parikh, USA

WS-07-003

Guidelines for the treatment of depression in specific populations: making decisions despite gaps in evidence

Glenda MacQueen, Canada

WS-07-004

Guidelines for the use of complementary and alternative medicines (CAM) in major depression

Arun Ravindran, Canada

T51: NEUROPSYCHOPATHOLOGY

WS-08

15:00–16:30

Functional neuroanatomy of hallucinations

Chair: *Rajesh Nagpal, India*

Co-Chair: *Harishchandra Gambheera, Sri Lanka*

WS-08-001

Functional neuroanatomy of auditory hallucinations

E. Mohandas Warriar, India

WS-08-002

Neural signature of visual hallucinations

Venu Gopal Jhanwar, India

WS-08-003

Neural mechanisms of somatic, musical and extracampine hallucinations

Anukant Mital, India

WS-08-004

The neural signature overlap between delusions and hallucinations

Debashis Ray, India

► Wednesday, 21 June 2017

T43: SCHIZOPHRENIA: BASIC/CLINICAL

WS-09

11:15–12:45

Schizophrenia research in Chile

Chair: *Hernan Silva, Chile*

Co-Chair: *Veronica Larach, Chile*

WS-09-001

BDNF as a biomarker of cognitive function in schizophrenia: A study in Chilean population

Hernan Silva, Chile

WS-09-002

Pragmatic and linguistic disorders in schizophrenia since the first episode

Eduardo Duran, Chile

WS-09-003

Atypical antipsychotics and psychosis spectrum: Chilean experience

Eugenio Olea, Chile

WS-09-004

Universal coverage for schizophrenia: The GES programme in Chile

Veronica Larach, Chile

T43: SCHIZOPHRENIA: BASIC/CLINICAL

WS-10

15:00–16:30

Evidence for brain stimulation methods in schizophrenia

Chair: *Joachim Cordes, Germany*

Co-Chair: *Christian Plewnia, Germany*

WS-10-001

Effects of transcranial direct current stimulation (tDCS) on executive functions

Christian Plewnia, Germany

WS-10-002

rTMS for the treatment of negative symptoms in residual schizophrenia

Joachim Cordes, Germany

WS-10-003

The treatment of hallucinations in schizophrenia spectrum disorders

Iris Sommer, The Netherlands

WS-10-004

Predictors of response to ECT in treatment-resistant schizophrenia

Tomasz Pawelczyk, Poland

The scientific programme of the WFSBP 2017 Congress will cover the following topics. Within each topic the track may be basic, clinical, interface or conceptual:

- | | |
|--|--|
| <ol style="list-style-type: none"> 1. Addictive Disorders 2. Antidepressants: Basic/Clinical 3. Antipsychotics: Basic/Clinical 4. Anxiety Disorders: Basic/Clinical 5. Anxiolytics: Basic/Clinical 6. Bipolar Disorders: Basic/Clinical 7. Childhood & Adolescent Disorders: Basic/Clinical 8. Chronobiology and Psychiatry 9. Cognitive Neuroscience 10. Dementia: Basic/Clinical 11. Depression: Basic/Clinical 12. Eating Disorders: Basic/Clinical 13. Emergency Psychiatry 14. Epidemiology 15. Ethics in Biological Psychiatry 16. Forensic Psychiatry 17. Genetics 18. Hypnotics: Basic/Clinical 19. Inflammation Psychiatry 20. Liaison Psychiatry 21. Mental Retardation or Chromosomal Aberrations: Basic/Clinical 22. Molecular Neurobiology 23. Mood Stabilisers: Basic/Clinical 24. Neuropathology 25. Neuroimaging: Genetic, Functional, Structural | <ol style="list-style-type: none"> 26. Neurophysiology 27. Obsessive-Compulsive Disorders: Basic/Clinical 28. Pain: Basic/Clinical 29. Panic Disorders: Basic/Clinical 30. Personality Disorders: Basic/Clinical 31. Pharmacoeconomics 32. Pharmacogenetics 33. Pharmacology 34. Phototherapy 35. Posttraumatic Stress: Basic/Clinical 36. Pregnancy, post partum and new born: Basic/Clinical 37. Premenstrual Syndrome: Basic/Clinical 38. Psychogeriatrics 39. Psychoneuroimmunology 40. Psychopathology 41. Psychosurgery 42. Psycho-Oncology 43. Schizophrenia: Basic/Clinical 44. Sexual Disorders: Basic/Clinical 45. Sleep Disorders: Basic/Clinical 46. Somatoform Disorders: Basic/Clinical 47. Stimulation Methods (ECT, TMS, VNS, DBS) 48. Stress: Basic/Clinical 49. Suicide: Basic/Clinical 50. Violence: Basic/Clinical 51. Miscellaneous |
|--|--|



Copenhagen, Nyhavn harbor @ tanya/fotolia.com



Call for Abstracts for Free Communications and Posters

Deadline for abstract submission: 6 December 2016

Notification of acceptance/rejection: Early March 2017

Authors of Free Communications or Posters are hereby kindly invited to submit an abstract for contributions to the WFSBP 2017 Congress by using the online submission form on the congress website www.wfsbp-congress.org.

Please note that online submission is mandatory.

Free Communications and Posters submitted individually and accepted by the International Scientific Programme Committee will be grouped by category topics into thematic sessions in order to promote communication among the presenters and participants and to allow for inspiring discussions.

FREE COMMUNICATIONS

Free Communications will be selected by the International Scientific Programme Committee after abstract submissions have been reviewed. The 90-minute sessions will be grouped by topics and chaired by selected specialists. The time slot for a single presentation in a Free Communication session is 15 minutes including discussion time. **Only 1 Free Communication abstract may be submitted per author.**

POSTERS

Each accepted poster will be exhibited at the WFSBP 2017 Copenhagen Congress at the Bella Center. The best posters will be grouped into thematic Guided Poster Tours chaired by renowned specialists. The Guided Poster Tours will give authors the opportunity to present their findings and discuss them with the audience.

A maximum of 4 posters abstracts may be submitted per author. The congress will deliver **WFSBP Young Investigator Awards** for the five best posters. Please refer to page 43 for further information.

Please note that accepted abstracts will be published only after completed registration and payment of the congress registration fee. The acceptance of submitted abstracts simultaneously results in binding registration of the speaker to attend the conference. **The registration fee must be paid immediately** after receiving the abstract acceptance, at the **latest until 20 March 2017**. Authors who have not settled the registration fee until that date will be omitted from the scientific programme. **Onsite registration for presenting authors is not possible.**

GUIDELINES FOR THE PREPARATION OF ABSTRACTS

Please submit your abstracts online and in English, the official language of the WFSBP Congress 2017.

- ▶ Please choose a title that clearly indicates the content of the contribution.
- ▶ Please avoid abbreviations in the title. Abbreviations may be used in the text if they are defined when used first.
- ▶ The author's name (full first name, family name) and place of work (institution, city, country) should be given. Degrees, titles, street addresses, and acknowledgments of support should be omitted, however.
- ▶ The abstract submission must be complete.
- ▶ Please choose a topic from the topic list.
- ▶ The text of the abstract should briefly state: **Objectives** (indicate the purpose of the study or the hypothesis that was tested), **Methods** (include the setting for the study, the subjects, the diagnosis or intervention, and the type of statistical analysis. If references are needed, they should be given in the text), **Results** (present as clearly as possible the outcome of the study and statistical significance if appropriate) and **Conclusions** (briefly discuss the data and emphasize the significance of the results). References need to be given in the text.
- ▶ The length of your abstract is limited to a maximum of 300 words.
- ▶ Please ensure that the abstract does not contain spelling, grammar or scientific errors, as it will be reproduced exactly as submitted. Submitted abstracts will not be edited in any way. If the abstract does not fulfill the necessary requirements it cannot be published.
- ▶ A disclosure of the existence of any significant financial interest or other affiliations with a funding organisation or with a commercial supporter of the session and/or provider of commercial services is required.
- ▶ All abstracts will be published online in the scientific programme of the WFSBP Congress from April 2017.
- ▶ **Only 1 Free Communication Abstract/Young Scientist Award Abstract may be submitted per author.**
- ▶ **A maximum of 4 posters may be submitted by each author.**

Submission Procedure

Abstracts for Free Communications, Young Scientist Awards and Posters have to be submitted electronically by using the online form on the congress website

www.wfsbp-congress.org.

Detailed instructions regarding the electronic submission procedure can be found on the website.

For any further assistance, please contact the congress and exhibition office:

CPO HANSER
SERVICE

Phone: +49-30-300 669-0

Email: wfsbp2017@cpo-hanser.de

We organize your success

CPO HANSER SERVICE is specialized in the field of Conference, Event, Destination Management and, ssoiation Management and has been organizing events of any size throughout Germany and worldwide for more than 35 years.

CPO HANSER
SERVICE

CONFERENCE – EVENT – DESTINATION – ASSOCIATION MANAGEMENT

We offer you:

- the best congress organization
- state-of-the-art online solutions
- electronic abstract handling
- CME accreditation handling
- effective congress technology
- sponsoring and exhibition acquisition and management
- finance management
- professional tax solutions
- creative event programs
- inhouse graphic design

BERLIN

Paulsborner Str. 44
14193 Berlin, Germany
phone +49-30-300 669 0
fax +49-30-305 73 91
email berlin@cpo-hanser.de

HAMBURG

Zum Ehrenhain 34
22885 Barsbüttel, Germany
phone +49-40-670 882 0
fax +49-40-670 32 83
email hamburg@cpo-hanser.de

www.cpo-hanser.de





Format Descriptions of the Scientific Sessions

OPENING LECTURE

The Opening Lecture will be held during the Opening Ceremony on 18 June 2017.

PLENARY LECTURES

Plenary Lectures are 45-minute sessions held by renowned experts. The speakers have been chosen among the most prominent researchers in the respective field.

DEBATES

Debates are intended to offer a platform for a lively, yet balanced discussion on controversial issues. A moderator (chairperson) and two speakers (one proponent and one opponent) will state their opinions on different subjects.

WFSBP TASK FORCE SYMPOSIA

A good number of WFSBP Task Forces have submitted Symposia organised by their key members on issues related to their field of special expertise. All of them have been included in the scientific programme and pertain to Treatment Guidelines, Consensus Statements and other hot topics in their respective thematic areas.

WFSBP TASK FORCE WORKSHOPS

A good number of WFSBP Task Forces have submitted Workshops organised by their key members on issues related to their field of special expertise. All of them have been included in the scientific programme and pertain to Treatment Guidelines, Consensus Statements and other hot topics in their respective thematic areas.

SYMPOSIA

Symposia are selected, covering basic, clinical, interface, and conceptual topics of Biological Psychiatry. Symposia are 90-minute sessions and will be organised and chaired by the experts whose proposals are accepted by the International Scientific Programme Committee.

WORKSHOPS

Workshops are 90-minute highly interactive sessions with an educational focus. This format is designed to give specific regions a platform for presentation and networking.

FREE COMMUNICATIONS

Authors are invited to submit abstracts on their latest research findings. All submitted abstracts will be reviewed and the best will be selected and allocated to Free Communication Sessions.

GUIDED POSTER TOURS

Abstracts on new research findings and/or major research efforts are expected to be submitted for the poster category. For those abstracts which will be submitted by young investigators for the poster category, the Local Organising Committee will arrange Guided Poster Tours to give the authors the opportunity to present these findings and discuss them with the audience.

EDUCATIONAL GRANT SESSIONS

(Young Scientists Award Sessions)

These sessions are dedicated to young researchers up to 40 years of age which will be pre-selected via an application process. Herewith the WFSBP is promoting education for talented young researchers. Interactional and practical learning is in the focus of these sessions. The educational grant sessions are open to all congress delegates.

INDUSTRY SPONSORED SYMPOSIA

These 60- to 90-minute sessions are fully integrated into the congress. The sessions are organised and executed by the pharmaceutical industry by unrestricted educational grants.

CME ACCREDITATION

An application will be made to the EACCME® for CME accreditation of this event.

WFSBP Awards

The following WFSBP Awards will be delivered and presented during the 13th World Congress of Biological Psychiatry 2017 in Copenhagen.

► WFSBP Lifetime Achievement Award in Biological Psychiatry

The WFSBP Lifetime Achievement Award in Biological Psychiatry is intended for senior research scientists (MD, PhD or equivalent) whose lifework has significantly influenced today's field of biological psychiatry. This award is open to members and non-members of the WFSBP. It consists of a monetary award of EUR 1,000.

► WFSBP Award for Scientific Excellence of the WFSBP Host

The WFSBP Award for Scientific Excellence of the WFSBP Host is dedicated to an outstanding researcher in the field of Biological Psychiatry originating from the host country of the World Congress of Biological Psychiatry. This award consists of a monetary award of EUR 1,000.

► WFSBP Research Prize

The WFSBP Research Prize is intended for WFSBP members (MD, PhD or equivalent) whose current scientific work has had an important impact in the field of clinical and/or basic research in the area of biological psychiatry. This prize consists of a monetary award of EUR 1,000.

► WFSBP Award for Excellence in Education

The WFSBP Award for Excellence in Education is to acknowledge outstanding and innovative education in biological psychiatry including the implementation of new interactive media. The WFSBP Education prize is open to all WFSBP members who have improved the education in all fields of Psychiatry. This award consists of a monetary award of EUR 1,000.

► WFSBP Young Investigator Awards for the five best posters (under 40 year-old)

An application for the Young Investigator Award is not necessary. All posters will be evaluated at the congress. The awards will go to those presentations that not only provide evidence of innovative research, but which are also well presented.

Please note that presenting authors must register and attend the meeting to be eligible for any of these awards.

Applications must be sent by e-mail to the congress and exhibition office:

CPO**HANSER**[®]
SERVICE

Phone: +49-30-300 669-0

Email: wfsbp2017@cpo-hanser.de

by 6 December 2016 and should include a short summary of the work and a brief CV. The letter should outline the main professional activities and provide key peer review publications. Prizes will be announced during the Opening Ceremony. Poster prizes will be delivered during the Closing Ceremony.

Congress Information

Congress Registration for the 13th World Congress of Biological Psychiatry is available via the congress website at www.wfsbp-congress.org.

Registration and payment received	Early registration by 25 January 2017 EUR	Late registration by 31 May 2017 EUR	On-site registration after 31 May 2017 EUR
WFSBP Members	530	630	730
Non-Members	630	730	830
Participants from Low-Income Countries*	290	390	490
Trainees**	290	390	490

* According to the Low-Income-Countries defined by the world bank. Please see the list on the WFSBP website www.wfsbp-congress.org

** Trainee / Student status must be confirmed by certificate in writing by head of department and is applicable only for participants born after 1 Jan 1982. Please send your certificate by email or fax to: CPO HANSER SERVICE GmbH, Fax: +49-30-305 73 91, Email: wfsbp2017@cpo-hanser.de

PAYMENT

When registering for the WFSBP 2017 Congress in Copenhagen, please arrange for payment of the registration fee. All payments should be made in EURO. You may choose between two modes of payment: **credit card payment** or **bank transfer**. Especially for payment made from outside Germany where the congress office is based, we strongly recommend credit card payments as charges for bank transfers may apply twice, once in the country of origin and a second time in Germany.

Please choose one mode of payment:

Credit card: AMEX, Mastercard or VISA

or bank transfer to the congress bank account:

CPO HANSER SERVICE w/WFSBP ZB 2017

Deutsche Bank Privat- u. Geschäftskunden AG, Berlin/

Bank Code: 1007 0024

Account Number: 108 96 97 02

BIC: DEUT DE DB BER

IBAN: DE 45 1007 0024 0108 9697 02

CONFIRMATION

Upon receipt of the registration and the corresponding payment, the congress office will send a confirmation form which also serves as an invoice. Please show this confirmation of registration at the congress counter when picking up your congress materials.

CANCELLATION OF CONGRESS PARTICIPATION

Notice of cancellation should be sent in writing only to the Congress Office CPO HANSER SERVICE. In case of cancellation by 25 January 2017 the payment will be refunded, minus a handling charge of 25%. No refund will be made after 25 January 2017.

ON-SITE REGISTRATION AFTER 31 MAY 2017

On-site registration will be possible but we recommend to register well in advance. Participants who wish to register on-site are advised to arrive early. On-site registration does not entitle participants to receive a delegate bag. On-site registration will be handled on a first-come, first-served basis, priority will be given to pre-registered delegates.

General Information

CONGRESS VENUE

Bella Center Copenhagen
Center Boulevard 5
2300 Copenhagen S, Denmark
Entrance: Congress Foyer

CONGRESS REGISTRATION DESK

The congress counter will be located in the Foyer.

Preliminary opening hours	
Saturday, 17 June 2017	16:00–19:00
Sunday, 18 June 2017	07:30–19:00
Monday, 19 June 2017	08:00–18:30
Tuesday, 20 June 2017	08:00–18:30
Wednesday, 21 June 2017	08:00–18:30
Thursday, 22 June 2017	08:00–17:30

CONGRESS AND EXHIBITION OFFICE

CPO
HANSER
SERVICE

Phone: +49–30–300 669-0
Email: wfsbp2017@cpo-hanser.de

POSTER EXHIBITION

Posters will be displayed from Monday, 19 June to Thursday, 22 June 2017 in Hall A 1 next to the technical exhibition. Each congress day there will be one Guided Poster Tour with the best posters only. The posters selected for the Guided Poster Tour will be displayed in a special area of the congress center. During the review of the abstracts which is done by the Local Organising Committee, the reviewers will indicate the candidates for the Guided Poster Tours. All other posters will be displayed for one entire congress day and grouped according to topics.

Information regarding poster format, set-up and dismantling will be sent to the authors along with their notification of acceptance.

TECHNICAL EXHIBITION

The WFSBP Congress 2017 will be accompanied by a major technical exhibition taking place in Hall A 1 of the Bella Center. Potential exhibitors can request an exhibition/sponsoring brochure from the exhibition office CPO HANSER SERVICE.

Email: wfsbp2017@cpo-hanser.de

Preliminary opening hours	
Monday, 19 June 2017	09:00–17:00
Tuesday, 20 June 2017	09:00–17:00
Wednesday, 21 June 2017	09:00–17:00

CONGRESS INFORMATION SYSTEM / CO CONGRESS ONLINE®

The web based Congress Information System CO CONGRESS ONLINE® has been installed at www.wfsbp-congress.org

Prior to the congress, CO CONGRESS ONLINE® will provide information on:

- ▶ Preparation of the congress
- ▶ List of topics
- ▶ Call for abstracts
- ▶ Invited speakers and invited conveners of symposia
- ▶ Preliminary scientific programme
- ▶ Accepted abstracts
- ▶ List of exhibitors
- ▶ Information about the main sponsors
- ▶ Copenhagen
- ▶ Hotel accommodation
- ▶ Travel to Copenhagen
- ▶ Special news
- ▶ Private mailbox

In due time, the final programme will be published on CO CONGRESS ONLINE® which enables each participant to create her/his personal congress programme schedule. CO CONGRESS ONLINE® offers an extensive congress service.



General Information

FINAL PROGRAMME

The final programme and abstracts will be published on the Internet at www.wfsbp-congress.org prior to the congress.

WFSBP 2017 CONGRESS APP MOBILE

The WFSBP 2017 Congress App is free for congress participants and provides iPhone/iPad and android smartphone users at WFSBP 2017 in Copenhagen with on-the-go access to the congress. The most up-to-date congress schedule is available at the fingertips during the congress.

CONGRESS LANGUAGE

The official language of the WFSBP Congress 2017 is English. Simultaneous translation will not be provided.

LETTER OF INVITATION

The congress will be pleased to send a formal letter of invitation to any registered delegate requesting one. It is understood that such an invitation is intended to help potential delegates to raise funds or to obtain a visa. This does not imply a commitment from the congress to provide any financial support. Letters of invitation may be requested from the congress office.

VISA

The entry formalities for Denmark vary according to the country of origin. The Ministry of Foreign Affairs of Denmark provides a list of countries that require a visa to enter the country. Please visit the website [http:// um.dk/en](http://um.dk/en).

OFFICIAL ITALIAN AGENCY

For Italian delegates only:

Any Italian pharmaceutical company supporting or participating in a congress abroad, is subjected to an authorization by AIFA (Italian Drug Agency), according to an Italian Government Decree (Decreto Legislativo 219/06 – art. 124). The request of authorization must be submitted within 60 days before the starting date of the event. The appointed agency to collect all applications from pharmaceutical companies and file them with the AIFA is:

AIM Group International – AIM Education S.r.l.

Valentina Disabato/Cristina Ghidoli

Via G. Ripamonti, 129 | 20141 Milan, Italy

Phone: +39-02-56601.288/360

Fax: +39-02-70048585

Email: aifa@aimgroup.eu

www.aimgroupinternational.com

INSURANCE

Please note that the congress fee does not include insurance. All participants should arrange for their own insurance. Health and accident insurance is strongly recommended and will need to be purchased in the country of origin.

FORCE MAJEURE

For reasons beyond its control (such as war, strikes, lock-outs, riots or any such civil disturbances, any natural disaster, including but not limited to earthquakes, floods, droughts and typhoons and any other cause of circumstance of whatsoever nature beyond control) that have an impact on the arrangements, timetables or planning of the 13th World Congress of Biological Psychiatry (WFSBP 2017) and its corresponding activities in Copenhagen, WFSBP has the right to immediately alter or cancel the activities or events or any of the arrangements, timetables, plans or other items relating directly or indirectly thereto. No party involved shall be entitled to any compensation for damages that result from such alteration or cancellation.

CURRENCY

The Danish currency is the Danish Krone (DKK). The Danish Krone is pegged to the Euro and convertible on world currency markets. The exchange rate fluctuates daily depending on the money market.

www.oanda.com

CLIMATE

Copenhagen is in the oceanic climate zone. Summer months are moderately warm and quite pleasant. June is the sunniest month of the year with an average of about eight hours of sunshine a day and the temperature varies between 11°C (52 °F) and 19°C (66°F).

TRAVEL TO COPENHAGEN AND BELLA CENTER

By plane Copenhagen is easy accessible from many European airports with direct flight connections. It is the largest airport in Scandinavia. From Copenhagen Airport it takes 10 minutes to reach the Bella Center. A regional train runs from the airport to Ørestad Station, the train station of the Bella Center.

By train Copenhagen Central Station is located in the heart of the city, bordering to the rough but also trendy Vesterbro. It is a gateway to all public transportation in and out and around Copenhagen. From Copenhagen Central Station it takes approx. 10 minutes by metro to reach the Bella Center. The name of the metro station is also Bella Center.

General Information

By car Bella Center is located at Center Boulevard 5, 2300 Copenhagen S. Follow the „Airport Motorway“, E20. The exit to Center Boulevard is number 19 and is called „Ørestad“ with „Bella Center“ listed below.

PUBLIC TRANSPORTATION IN COPENHAGEN

Public transportation in Copenhagen is reliable, punctual, and it goes everywhere in the city. In Copenhagen the trains, metro and busses (including waterbuses) can be accessed with the same ticket. All you need to know is how many zones you will pass on your journey. Note the metro will take you from the airport to central Copenhagen in only 13 minutes.

TAXIS TO BELLA CENTER

Bella Center is just a 10 – 15 minute taxi drive from Copenhagen Central Station and not more than 10 minutes from Copenhagen Airport by taxi. A taxi from Bella Center to the city centre costs about DKK 200-250. A taxi from Bella Center to Copenhagen Airport costs about DKK 150-200.



© Chefsamba/Fotolia.com

HOTELS IN COPENHAGEN

CPO HANSER SERVICE GmbH has reserved a large number of hotel rooms in various hotels in different price categories in Copenhagen. The majority of the hotel rooms are located close to Bella Center.

Reservations will be possible via **CO HotelOnline**® on the website www.wfsbp-congress.org. Bookings by email or telephone cannot be accepted.

CPO HANSER SERVICE

CPO HANSER
SERVICE

Phone: +49-30-300 669-0

Email: wfsbp2017@cpo-hanser.de

CITY OF COPENHAGEN

Copenhagen is not only the capital of Denmark. It is a cultural and economic center of Northern Europe. More than 1,2 million citizens live in the greater Copenhagen region.

The city is located on the Danish Island „Sælland“ (Danish: Sjælland) and next to the „Øresund“ – a Baltic sea seagate and natural borderline to Sweden. Due to this geographic location, Copenhagen – together with the Swedish city Malmö – represents the binational „Øresund Region“. It is a unique metropolis area, where two countries and cities are connected via the 8 km „Øresund Bridge“.

The Copenhagen Palaces Christiansborg and Amalienborg are the seat of the Danish Parliament and the residence of the Danish Queen Margrethe II. Architecture, design and music make Copenhagen an outstanding cultural hotspot in Northern Europe. It is famous for its innovative improvements which can be seen and experienced throughout the city.

Also, Copenhagen has great museums to offer, for example Louisiana and The National Gallery of Denmark. The Royal Danish Opera, located directly at the harbor front, is combining modern Danish architecture with international performances. The main sightseeing spots and touristic attractions are the Tivoli Gardens, Christiansborg, and of course the „Little Mermaid“ – the famous sculpture of Edvard Eriksen at the waterside.

The University of Copenhagen is offering a wide range of academic disciplines. With over 40,000 students and more than 9,000 employees, the University of Copenhagen is one of the largest institutions of research and education in the Nordic countries.

Due to short distances within the city of Copenhagen, its good public transportation system, and especially the well developed cycle paths, Copenhagen is a convenient place for meetings.



Dates to remember

6 December 2016	Deadline for abstract submission for free communications and posters
25 January 2017	Deadline early bird registration
31 May 2017	Deadline late registration
18 June 2017	Opening Ceremony and Networking Reception